The	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
ORI1yt	I-DNA
enhancer	I-DNA
is	O
not	O
B-cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	B-protein
transcription	I-protein
factors	I-protein
R	I-protein
and	I-protein
Z	I-protein
.	O

The	O
Epstein-Barr	B-DNA
virus	I-DNA
DR	I-DNA
promoter	I-DNA
is	O
located	O
upstream	O
of	O
the	O
PstI	B-DNA
repeats	I-DNA
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	B-DNA
box	I-DNA
,	O
it	O
contains	O
an	O
upstream	B-DNA
region	I-DNA
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	B-protein
(	I-protein
Z	I-protein
)	I-protein
(	O
the	O
BZLF1-encoded	B-protein
transcription	I-protein
factor	I-protein
)	O
and	O
an	O
enhancer	B-DNA
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	B-DNA
.	O

Domain	B-DNA
B	I-DNA
has	O
been	O
described	O
as	O
a	O
B-cell-specific	B-DNA
EB1-responsive	I-DNA
element	I-DNA
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040-3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	B-protein
and	O
R	B-protein
,	O
an	O
EBV	B-protein
early	I-protein
product	I-protein
encoded	O
by	O
the	O
open	B-DNA
reading	I-DNA
frame	I-DNA
BRLF1	I-DNA
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313-321	O
,	O
1990	O
)	O
.	O

We	O
show	O
here	O
that	O
domain	B-DNA
B	I-DNA
is	O
an	O
R-responsive	B-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	B-DNA
B-cell-specific	I-DNA
element	I-DNA
.	O

However	O
,	O
there	O
is	O
an	O
EB1-binding	B-DNA
site	I-DNA
(	O
ZRE-B	B-DNA
)	O
located	O
within	O
the	O
R-responsive	B-DNA
enhancer	I-DNA
region	I-DNA
.	O

ZRE-B	B-DNA
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R-dependent	O
enhancer	O
activity	O
.	O

Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	B-protein
and	O
EB1	B-protein
when	O
activating	O
the	O
B	B-DNA
domain	I-DNA
(	O
ZRE-B	B-DNA
plus	O
the	O
R-responsive	B-DNA
element	I-DNA
)	O
positioned	O
as	O
an	O
enhancer	B-DNA
.	O

ZRE-B	B-DNA
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	B-DNA
inducible	I-DNA
enhancer	I-DNA
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	B-DNA
enhancer	I-DNA
B	B-DNA
domain	I-DNA
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R-activating	O
signal	O
to	O
the	O
rabbit	B-DNA
beta-globin	I-DNA
promoter	I-DNA
.	O

We	O
found	O
that	O
the	O
R-responsive	B-DNA
element	I-DNA
is	O
composed	O
of	O
four	O
protoenhancers	B-DNA
that	O
span	O
the	O
whole	O
B	B-DNA
domain	I-DNA
.	O

These	O
protoenhancers	B-DNA
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	B-protein
.	O

One	O
of	O
the	O
protoenhancers	B-DNA
contains	O
the	O
overlapping	B-DNA
palindromes	I-DNA
5'-TTGTCCcgtGGACAAaTGTCC-3'	O
.	O

However	O
,	O
one	O
palindrome	B-DNA
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	B-DNA
palindromes	I-DNA
did	O
not	O
respond	O
to	O
R	O
.	O

JoURNAL	NULL
oF	NULL
ViroLoGy	NULL
,	NULL
June	NULL
1990	NULL
,	NULL
p.	NULL
2810-2818	NULL
0022-538	NULL
X/90/062810-09	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

6	NULL
The	NULL
Epstein-Barr	NULL
Virus	NULL
(	NULL
EBV	NULL
)	NULL
ORJI	NULL
;	NULL
,	NULL
,	NULL
,	NULL
Enhancer	NULL
Is	NULL
Not	NULL
B-Cell	NULL
Specific	NULL
and	NULL
Does	NULL
Not	NULL
Respond	NULL
Synergistically	NULL
to	NULL
the	NULL
EBV	NULL
Transcription	NULL
Factors	NULL
R	NULL
and	NULL
Z	NULL
HENRI	NULL
GRUFFAT	NULL
,	NULL
NANCY	NULL
MORENO	NULL
,	NULL
anp	NULL
ALAIN	NULL
SERGEANT*	NULL
Laboratoire	NULL
de	NULL
Virologie	NULL
Moléculaire	NULL
,	NULL
Ecole	NULL
Normale	NULL
Supérieure	NULL
de	NULL
Lyon	NULL
,	NULL
46	NULL
,	NULL
Allée	NULL
d'Italie	NULL
,	NULL
69364	NULL
Lyon	NULL
Cedex	NULL
07	NULL
,	NULL
France	NULL
Received	NULL
26	NULL
October	NULL
1989/Accepted	NULL
12	NULL
March	NULL
1990	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
DR	NULL
promoter	NULL
is	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
Psfl	NULL
repeats	NULL
,	NULL
and	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
it	NULL
contains	NULL
an	NULL
upstream	NULL
region	NULL
(	NULL
positions	NULL
-69	NULL
to	NULL
-220	NULL
)	NULL
responsive	NULL
to	NULL
EB1	NULL
(	NULL
Z	NULL
)	NULL
(	NULL
the	NULL
BZLF1-encoded	NULL
transcription	NULL
factor	NULL
)	NULL
and	NULL
an	NULL
enhancer	NULL
with	NULL
two	NULL
functionally	NULL
distinct	NULL
domains	NULL
,	NULL
A	NULL
and	NULL
B.	NULL
Domain	NULL
B	NULL
has	NULL
been	NULL
described	NULL
as	NULL
a	NULL
B-cell-specific	NULL
EB1-responsive	NULL
element	NULL
(	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
,	NULL
J.	NULL
Virol	NULL
.	NULL

63:3040-3050	NULL
,	NULL
1989	NULL
)	NULL
activated	NULL
synergistically	NULL
by	NULL
EB1	NULL
and	NULL
R	NULL
,	NULL
an	NULL
EBV	NULL
early	NULL
product	NULL
encoded	NULL
by	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
BRLFI1	NULL
(	NULL
M.	NULL
A.	NULL
Cox	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
J.	NULL
Virol	NULL
.	NULL

64:313-321	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
domain	NULL
B	NULL
is	NULL
an	NULL
R-responsive	NULL
element	NULL
in	NULL
HeLa	NULL
cells	NULL
and	NULL
is	NULL
therefore	NULL
not	NULL
an	NULL
EBl-responsive	NULL
B-cell-specific	NULL
element	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
an	NULL
EBl-binding	NULL
site	NULL
(	NULL
ZRE-B	NULL
)	NULL
located	NULL
within	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
region	NULL
.	NULL

ZRE-B	NULL
can	NULL
be	NULL
deleted	NULL
without	NULL
affecting	NULL
the	NULL
R-dependent	NULL
enhancer	NULL
activity	NULL
.	NULL

Moreover	NULL
,	NULL
there	NULL
is	NULL
no	NULL
cooperation	NULL
or	NULL
synergy	NULL
between	NULL
R	NULL
and	NULL
EB1	NULL
when	NULL
activating	NULL
the	NULL
B	NULL
domain	NULL
(	NULL
ZRE-B	NULL
plus	NULL
the	NULL
R-responsive	NULL
element	NULL
)	NULL
positioned	NULL
as	NULL
an	NULL
enhancer	NULL
.	NULL

ZRE-B	NULL
is	NULL
therefore	NULL
not	NULL
part	NULL
of	NULL
the	NULL
R-inducible	NULL
enhancer	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
several	NULL
subregions	NULL
of	NULL
the	NULL
DR	NULL
enhancer	NULL
B	NULL
domain	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
,	NULL
for	NULL
their	NULL
capacity	NULL
to	NULL
transmit	NULL
the	NULL
R-activating	NULL
signal	NULL
to	NULL
the	NULL
rabbit	NULL
B-globin	NULL
promoter	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
R-responsive	NULL
element	NULL
is	NULL
composed	NULL
of	NULL
four	NULL
protoenhancers	NULL
that	NULL
span	NULL
the	NULL
whole	NULL
B	NULL
domain	NULL
.	NULL

These	NULL
protoenhancers	NULL
alone	NULL
are	NULL
weakly	NULL
or	NULL
not	NULL
responsive	NULL
to	NULL
R.	NULL
One	NULL
of	NULL
the	NULL
protoenhancers	NULL
contains	NULL
the	NULL
overlapping	NULL
palindromes	NULL
S5'-TTGTCCegtGGACAAaTGTCC-3	NULL
'	NULL
.	NULL

However	NULL
,	NULL
one	NULL
palindrome	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
duplicated	NULL
,	NULL
or	NULL
the	NULL
overlapping	NULL
palindromes	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
R.	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
human	NULL
herpesvirus	NULL
which	NULL
infects	NULL
and	NULL
immortalizes	NULL
peripheral	NULL
B	NULL
lymphocytes	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
establishment	NULL
of	NULL
a	NULL
latent	NULL
infection	NULL
.	NULL

In	NULL
such	NULL
latently	NULL
infected	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
entire	NULL
EBV	NULL
genome	NULL
is	NULL
maintained	NULL
mainly	NULL
as	NULL
a	NULL
plasmid	NULL
,	NULL
and	NULL
its	NULL
expression	NULL
is	NULL
reduced	NULL
to	NULL
a	NULL
few	NULL
genes	NULL
,	NULL
those	NULL
encoding	NULL
the	NULL
following	NULL
:	NULL
two	NULL
small	NULL
RNAs	NULL
(	NULL
EBERS	NULL
)	NULL
(	NULL
28	NULL
)	NULL
,	NULL
the	NULL
six	NULL
nuclear	NULL
proteins	NULL
EBNA-1	NULL
,	NULL
-2	NULL
,	NULL
-3A	NULL
,	NULL
-3B	NULL
,	NULL
-3C	NULL
,	NULL
and	NULL
LP	NULL
(	NULL
32	NULL
)	NULL
,	NULL
the	NULL
BHRF1l-encoded	NULL
product	NULL
(	NULL
2	NULL
)	NULL
,	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
20	NULL
)	NULL
,	NULL
and	NULL
the	NULL
terminal	NULL
membrane	NULL
protein	NULL
,	NULL
whose	NULL
coding	NULL
sequence	NULL
is	NULL
created	NULL
by	NULL
joining	NULL
the	NULL
ends	NULL
of	NULL
the	NULL
linear	NULL
virus	NULL
(	NULL
27	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
latent	NULL
EBV	NULL
genome	NULL
is	NULL
spontaneously	NULL
activated	NULL
in	NULL
particular	NULL
cell	NULL
lines	NULL
,	NULL
in	NULL
which	NULL
between	NULL
0.5	NULL
and	NULL
5	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
produce	NULL
viruses	NULL
.	NULL

It	NULL
can	NULL
also	NULL
be	NULL
activated	NULL
by	NULL
various	NULL
chemical	NULL
agents	NULL
,	NULL
including	NULL
the	NULL
tumor	NULL
promoter	NULL
12-O-tetradecanoyl-phorbol-13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
(	NULL
31	NULL
,	NULL
38	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
the	NULL
activation	NULL
seems	NULL
to	NULL
be	NULL
linked	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
two	NULL
EBV-encoded	NULL
transactivators	NULL
of	NULL
early-gene	NULL
promoters	NULL
,	NULL
EB1	NULL
and	NULL
R	NULL
(	NULL
6	NULL
,	NULL
7	NULL
,	NULL
9	NULL
,	NULL
10	NULL
,	NULL
18	NULL
,	NULL
36	NULL
)	NULL
.	NULL

EB1	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
ORF	NULL
)	NULL
BZLF1	NULL
and	NULL
is	NULL
expressed	NULL
from	NULL
two	NULL
promoters	NULL
,	NULL
PZ	NULL
and	NULL
PR	NULL
,	NULL
either	NULL
as	NULL
a	NULL
1-kilobase	NULL
monocistronic	NULL
mRNA	NULL
or	NULL
as	NULL
3-	NULL
and	NULL
4-kilobase	NULL
mRNAs	NULL
generated	NULL
by	NULL
alternative	NULL
splicing	NULL
and	NULL
expressing	NULL
both	NULL
EB1	NULL
and	NULL
R	NULL
,	NULL
the	NULL
BRLF1	NULL
ORF-encoded	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

EB1	NULL
seems	NULL
to	NULL
have	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
lytic	NULL
cycle	NULL
(	NULL
6	NULL
,	NULL
9	NULL
,	NULL
10	NULL
,	NULL
32	NULL
)	NULL
.	NULL

It	NULL
is	NULL
a	NULL
DNA-binding	NULL
protein	NULL
(	NULL
13	NULL
)	NULL
that	NULL
positively	NULL
autoregulates	NULL
its	NULL
own	NULL
promoters	NULL
and	NULL
activates	NULL
transcription	NULL
from	NULL
quite	NULL
different	NULL
responsive	NULL
elements	NULL
,	NULL
including	NULL
AP-1-binding	NULL
sites	NULL
(	NULL
30	NULL
,	NULL
37	NULL
)	NULL
.	NULL

EB1	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
be	NULL
a	NULL
factor	NULL
that	NULL
can	NULL
act	NULL
at	NULL
distances	NULL
more	NULL
than	NULL
100	NULL
to	NULL
200	NULL
base	NULL
pairs	NULL
(	NULL
bp	NULL
)	NULL
from	NULL
the	NULL
TATA	NULL
box	NULL
(	NULL
37	NULL
)	NULL
.	NULL

R	NULL
seems	NULL
to	NULL
be	NULL
a	NULL
factor	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

2810	NULL
that	NULL
can	NULL
act	NULL
at	NULL
distances	NULL
of	NULL
thousands	NULL
of	NULL
base	NULL
pairs	NULL
,	NULL
and	NULL
two	NULL
R	NULL
targets	NULL
have	NULL
been	NULL
identified	NULL
:	NULL
one	NULL
in	NULL
the	NULL
EBV	NULL
DR/DL	NULL
enhancer	NULL
B	NULL
domain	NULL
(	NULL
5	NULL
)	NULL
and	NULL
one	NULL
in	NULL
the	NULL
promoter	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
EB2	NULL
,	NULL
the	NULL
BMLF1I-	NULL
and	NULL
BSLF2-encoded	NULL
posttranscriptional	NULL
activator	NULL
(	NULL
3	NULL
,	NULL
25	NULL
)	NULL
.	NULL

The	NULL
EBV	NULL
DR	NULL
promoter	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
DL	NULL
promoter	NULL
(	NULL
1	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
24	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

These	NULL
duplicate	NULL
promoters	NULL
are	NULL
located	NULL
100	NULL
kilobase	NULL
pairs	NULL
(	NULL
kbp	NULL
)	NULL
from	NULL
each	NULL
other	NULL
,	NULL
one	NULL
in	NULL
the	NULL
right	NULL
part	NULL
(	NULL
DR	NULL
)	NULL
and	NULL
the	NULL
other	NULL
in	NULL
the	NULL
left	NULL
part	NULL
(	NULL
DL	NULL
)	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
19	NULL
,	NULL
21	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
some	NULL
cis-acting	NULL
elements	NULL
of	NULL
the	NULL
DL	NULL
promoter	NULL
could	NULL
be	NULL
bidirectional	NULL
and	NULL
could	NULL
control	NULL
in	NULL
a	NULL
rightward	NULL
direction	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
EA-R	NULL
ORF	NULL
BHRF1	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
DR	NULL
and	NULL
DL	NULL
promoters	NULL
are	NULL
not	NULL
detectably	NULL
active	NULL
during	NULL
latency	NULL
.	NULL

However	NULL
,	NULL
after	NULL
disruption	NULL
of	NULL
latency	NULL
,	NULL
they	NULL
become	NULL
active	NULL
and	NULL
overlap	NULL
with	NULL
origins	NULL
of	NULL
replication	NULL
(	NULL
ORI	NULL
,	NULL
,	NULL
,	NULL
)	NULL
functional	NULL
only	NULL
during	NULL
the	NULL
lytic	NULL
cycle	NULL
(	NULL
17	NULL
)	NULL
.	NULL

ORI	NULL
;	NULL
,	NULL
,	NULL
activity	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
EBV-encoded	NULL
DNA	NULL
polymerase	NULL
(	NULL
17	NULL
)	NULL
,	NULL
the	NULL
BZLF1l-encoded	NULL
transcription	NULL
factor	NULL
EB1	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
enhancer	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
DR/DL	NULL
TATA	NULL
boxes	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
17	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
enhancer	NULL
has	NULL
two	NULL
domains	NULL
,	NULL
A	NULL
and	NULL
B.	NULL
Domain	NULL
A	NULL
is	NULL
constitutively	NULL
active	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
tested	NULL
but	NULL
does	NULL
not	NULL
function	NULL
in	NULL
lymphoid	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
domain	NULL
B	NULL
is	NULL
transactivated	NULL
by	NULL
R	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Domain	NULL
B	NULL
is	NULL
also	NULL
activated	NULL
by	NULL
EB1	NULL
,	NULL
but	NULL
only	NULL
in	NULL
EBV	NULL
genome-positive	NULL
cells	NULL
,	NULL
demonstrating	NULL
that	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
R	NULL
is	NULL
induced	NULL
by	NULL
EB1l	NULL
(	NULL
5	NULL
)	NULL
.	NULL

One	NULL
R	NULL
target	NULL
in	NULL
the	NULL
DR	NULL
enhancer	NULL
B	NULL
domain	NULL
has	NULL
been	NULL
reduced	NULL
to	NULL
28	NULL
bp	NULL
and	NULL
contains	NULL
the	NULL
double	NULL
palindromic	NULL
sequence	NULL
TTGTCCCGTGGACAATGTCC	NULL
.	NULL

Part	NULL
of	NULL
this	NULL
region	NULL
,	NULL
CCGTGGAGAATGTC	NULL
,	NULL
is	NULL
partially	NULL
conserved	NULL
in	NULL
the	NULL
R-inducible	NULL
enhancer	NULL
identified	NULL
in	NULL
the	NULL
EB2	NULL
promoter	NULL
(	NULL
3	NULL
,	NULL
8	NULL
,	NULL
25	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
this	NULL
28-bp	NULL
DNA	NULL
fragment	NULL
was	NULL
placed	NULL
upstream	NULL
from	NULL
the	NULL
rabbit	NULL
B-globin	NULL
promoter	NULL
,	NULL
this	NULL
promoter	NULL
became	NULL
responsive	NULL
to	NULL
R	NULL
,	NULL
but	NULL
the	NULL
level	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
A	NULL
Phir	NULL
BRLF	NULL
I	NULL
I	NULL
son	NULL
d	NULL
Bi	NULL
12113	NULL
A	NULL
Jnet	NULL
C	NULL
wwwyH	NULL
F	NULL
quroam	NULL
sl	NULL
E/grek	NULL
a	NULL
G	NULL
_	NULL
=_	NULL
A	NULL
Nhet	NULL
ale2e3	NULL
Tr	NULL
un	NULL
arn	NULL
uzrimz	NULL
us	NULL
123	NULL
ve	NULL
LJ	NULL
U5	NULL
-	NULL
te	NULL
'	NULL
EB	NULL
1	NULL
R	NULL
ire	NULL
i	NULL
pr	NULL
§	NULL
|	NULL
'	NULL
_	NULL
somain	NULL
A	NULL
a	NULL
domain	NULL
B	NULL
ENHANCER	NULL
4	NULL
|	NULL
-639	NULL
-137	NULL
-899	NULL
774	NULL
)	NULL
-752	NULL
~775	NULL
-012	NULL
L_	NULL
___	NULL
j	NULL
-737	NULL
-605	NULL
B	NULL
ﬁzz	NULL
size	NULL
of	NULL
S1	NULL
protected	NULL
fragments	NULL
S1	NULL
probe	NULL
cer	NULL
TACACTTGCTTT	NULL
TTACT	NULL
AMAA	NULL
/	NULL
rebd	NULL
(	NULL
t	NULL
S-glebin	NULL
Bgi	NULL
it	NULL
~PooRI-	NULL
Bomil	NULL
pars	NULL
22	NULL
-f-	NULL
sors22	NULL
(	NULL
Pull	NULL
)	NULL
_	NULL
SV40	NULL
|	NULL
(	NULL
Stui	NULL
)	NULL
Bgitt/Pvult	NULL
272	NULL
5193	NULL
[	NULL
3	NULL
1	NULL
5243	NULL
2	NULL
?	NULL

size	NULL
of	NULL
S1	NULL
protected	NULL
fragments	NULL
3s	NULL
I2	NULL
2	NULL
!	NULL

_s1	NULL
probe	NULL
numccéécsmcits	NULL
:	NULL
siénmummmcmccfczzé	NULL
TATITATECAGAGECCEAGSCCECCTGGSCCTCTGAGCTATTCCAGAAGTAGTGAGEAGSC	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
structures	NULL
of	NULL
DR	NULL
enhancer	NULL
mutations	NULL
and	NULL
of	NULL
S1	NULL
nuclease	NULL
DNA	NULL
probes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Two	NULL
EBV	NULL
ORFs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
code	NULL
for	NULL
transcription	NULL
factors	NULL
;	NULL
BZLF1	NULL
codes	NULL
for	NULL
EB1	NULL
,	NULL
and	NULL
BRLFI	NULL
codes	NULL
for	NULL
R.	NULL
One	NULL
target	NULL
each	NULL
(	NULL
MI	NULL
)	NULL
for	NULL
EB1	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
and	NULL
R	NULL
(	NULL
5	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
DR	NULL
promoter	NULL
.	NULL

The	NULL
R-responsive	NULL
region	NULL
denoted	NULL
domain	NULL
B	NULL
has	NULL
been	NULL
mutated	NULL
by	NULL
progressive	NULL
deletion	NULL
,	NULL
and	NULL
the	NULL
mutations	NULL
are	NULL
shown	NULL
(	NULL
thick	NULL
lines	NULL
)	NULL
.	NULL

Numbers	NULL
on	NULL
both	NULL
ends	NULL
of	NULL
the	NULL
thick	NULL
lines	NULL
indicate	NULL
the	NULL
endpoints	NULL
of	NULL
the	NULL
deletions	NULL
in	NULL
domain	NULL
B	NULL
with	NULL
respect	NULL
to	NULL
position	NULL
52788	NULL
as	NULL
-1	NULL
on	NULL
the	NULL
EBV	NULL
B95-8	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
structure	NULL
of	NULL
S1	NULL
nuclease	NULL
DNA	NULL
probes	NULL
and	NULL
size	NULL
of	NULL
the	NULL
Sl-protected	NULL
DNA	NULL
fragments	NULL
.	NULL

The	NULL
B-globin	NULL
and	NULL
SV40	NULL
early	NULL
TATA	NULL
boxes	NULL
are	NULL
underlined	NULL
.	NULL

of	NULL
activation	NULL
was	NULL
only	NULL
15	NULL
to	NULL
20	NULL
%	NULL
of	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
observed	NULL
when	NULL
domain	NULL
B	NULL
was	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
5	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
other	NULL
sequences	NULL
in	NULL
the	NULL
B	NULL
domain	NULL
were	NULL
required	NULL
in	NULL
order	NULL
to	NULL
have	NULL
a	NULL
fully	NULL
active	NULL
R-responsive	NULL
element	NULL
(	NULL
RRE	NULL
)	NULL
.	NULL

However	NULL
,	NULL
recent	NULL
reports	NULL
are	NULL
at	NULL
odds	NULL
with	NULL
the	NULL
above	NULL
results	NULL
and	NULL
suggest	NULL
that	NULL
the	NULL
B	NULL
domain	NULL
is	NULL
in	NULL
fact	NULL
a	NULL
B-cell-specific	NULL
enhancer	NULL
induced	NULL
by	NULL
EB1	NULL
(	NULL
29	NULL
)	NULL
and	NULL
responds	NULL
synergistically	NULL
to	NULL
EB1	NULL
and	NULL
R	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
demonstrate	NULL
and	NULL
confirm	NULL
that	NULL
the	NULL
ORI	NULL
;	NULL
,	NULL
,	NULL
enhancer	NULL
is	NULL
not	NULL
a	NULL
B-cell-specific	NULL
EBl-responsive	NULL
element	NULL
.	NULL

It	NULL
is	NULL
in	NULL
fact	NULL
induced	NULL
by	NULL
R	NULL
and	NULL
does	NULL
not	NULL
respond	NULL
synergically	NULL
to	NULL
Z	NULL
and	NULL
R	NULL
when	NULL
positioned	NULL
as	NULL
an	NULL
enhancer	NULL
.	NULL

In	NULL
our	NULL
study	NULL
,	NULL
we	NULL
also	NULL
defined	NULL
more	NULL
precisely	NULL
the	NULL
sequences	NULL
involved	NULL
in	NULL
the	NULL
enhancer	NULL
function	NULL
described	NULL
above	NULL
.	NULL

We	NULL
synthesized	NULL
double-stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
DNA	NULL
subfragments	NULL
of	NULL
domain	NULL
B	NULL
of	NULL
the	NULL
DR	NULL
enhancer	NULL
.	NULL

The	NULL
enhancer	NULL
activity	NULL
of	NULL
these	NULL
oligonucleotides	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
as	NULL
various	NULL
heterodimers	NULL
,	NULL
was	NULL
evaluated	NULL
as	NULL
their	NULL
ability	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
the	NULL
rabbit	NULL
B-globin	NULL
promoter	NULL
after	NULL
cotransfection	NULL
into	NULL
HeLa	NULL
cells	NULL
with	NULL
an	NULL
R-expressing	NULL
vector	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
RRE	NULL
is	NULL
located	NULL
in	NULL
a	NULL
75-bp	NULL
DNA	NULL
fragment	NULL
containing	NULL
three	NULL
regions	NULL
which	NULL
are	NULL
weakly	NULL
or	NULL
not	NULL
responsive	NULL
to	NULL
R.	NULL
However	NULL
,	NULL
these	NULL
three	NULL
regions	NULL
are	NULL
required	NULL
in	NULL
order	NULL
to	NULL
obtain	NULL
a	NULL
full	NULL
R-responsive	NULL
enhancer	NULL
and	NULL
might	NULL
therefore	NULL
act	NULL
cooperatively	NULL
.	NULL

ORL	NULL
,	NULL
,	NULL
ENHANCER	NULL
TRANSACTIVATION	NULL
2811	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Cloned	NULL
DNA	NULL
templates	NULL
.	NULL

The	NULL
EB1-	NULL
and	NULL
R-expressing	NULL
vectors	NULL
have	NULL
been	NULL
described	NULL
extensively	NULL
elsewhere	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
they	NULL
are	NULL
pUC18	NULL
derivatives	NULL
containing	NULL
the	NULL
ORFs	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
,	NULL
which	NULL
code	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
the	NULL
EBV	NULL
transactivat-ing	NULL
factors	NULL
EB1	NULL
and	NULL
R	NULL
,	NULL
placed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
early	NULL
promoter-enhancer	NULL
.	NULL

Plasmids	NULL
pG1	NULL
and	NULL
pG2	NULL
contain	NULL
the	NULL
rabbit	NULL
B-globin	NULL
gene	NULL
with	NULL
the	NULL
Ml3mp12	NULL
polylinker	NULL
cloned	NULL
5	NULL
'	NULL
to	NULL
the	NULL
-globin	NULL
promoter	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Plasmids	NULL
pG2.899/741	NULL
,	NULL
pG2.899/752	NULL
,	NULL
pG2.899/775	NULL
,	NULL
pG2.899/812	NULL
,	NULL
pG2.737/805	NULL
,	NULL
pG2.765/737	NULL
,	NULL
pG2.765/7372x	NULL
,	NULL
pG2.765/754	NULL
,	NULL
pG2.765/754x2	NULL
,	NULL
pG2.764/752	NULL
,	NULL
pG2.783/761	NULL
,	NULL
pG2.810/789	NULL
,	NULL
pG2.764/745	NULL
,	NULL
pG2.781/752	NULL
,	NULL
pG2.783/737	NULL
,	NULL
pG2.783/741	NULL
,	NULL
and	NULL
pG2.899/812	NULL
were	NULL
made	NULL
by	NULL
ligating	NULL
subregions	NULL
of	NULL
the	NULL
B	NULL
domain	NULL
of	NULL
the	NULL
DR	NULL
enhancer	NULL
425	NULL
bp	NULL
5	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2B	NULL
and	NULL
3B	NULL
)	NULL
.	NULL

Plasmids	NULL
pG1.899/741	NULL
and	NULL
pG1.741/899	NULL
were	NULL
made	NULL
by	NULL
ligating	NULL
domain	NULL
B	NULL
in	NULL
both	NULL
orientations	NULL
-109	NULL
bp	NULL
5	NULL
'	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Plasmid	NULL
pG1.741/899	NULL
was	NULL
opened	NULL
at	NULL
the	NULL
unique	NULL
Xbal	NULL
site	NULL
,	NULL
digested	NULL
with	NULL
BAL	NULL
31	NULL
nuclease	NULL
,	NULL
treated	NULL
with	NULL
T4	NULL
DNA	NULL
polymerase	NULL
,	NULL
and	NULL
recircularized	NULL
.	NULL

In	NULL
one	NULL
of	NULL
the	NULL
deletion	NULL
mutants	NULL
pG3.741/861	NULL
;	NULL
see	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
,	NULL
Z-responsive	NULL
element	NULL
B	NULL
(	NULL
ZRE-B	NULL
)	NULL
was	NULL
brought	NULL
-106	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
B-globin	NULL
+1	NULL
.	NULL

Plasmid	NULL
pG4.741/899	NULL
was	NULL
generated	NULL
by	NULL
ligating	NULL
domain	NULL
B	NULL
in	NULL
inverted	NULL
orientation	NULL
37	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
B-globin	NULL
TATA	NULL
box	NULL
.	NULL

All	NULL
clones	NULL
were	NULL
verified	NULL
by	NULL
sequencing	NULL
.	NULL

Numbers	NULL
after	NULL
pG2	NULL
or	NULL
pG1	NULL
describe	NULL
the	NULL
position	NULL
and	NULL
the	NULL
orientation	NULL
of	NULL
the	NULL
border	NULL
of	NULL
the	NULL
inserted	NULL
B	NULL
domain	NULL
subregions	NULL
and	NULL
refer	NULL
to	NULL
the	NULL
map	NULL
coordinates	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
2A	NULL
.	NULL

Plasmid	NULL
pSV2	NULL
$	NULL
B	NULL
(	NULL
3	NULL
)	NULL
expresses	NULL
a	NULL
chimeric	NULL
SV40-B-globin	NULL
RNA	NULL
and	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
transient-expression	NULL
experiments	NULL
.	NULL

Plasmid	NULL
pSVO	NULL
contains	NULL
the	NULL
SV40	NULL
Haplt	NULL
(	NULL
map	NULL
position	NULL
346	NULL
)	NULL
-to-HindlIII	NULL
(	NULL
map	NULL
position	NULL
5171	NULL
)	NULL
fragment	NULL
cloned	NULL
in	NULL
pUC19	NULL
digested	NULL
with	NULL
HindIII	NULL
and	NULL
BamHI	NULL
.	NULL

This	NULL
plasmid	NULL
was	NULL
included	NULL
in	NULL
transfections	NULL
to	NULL
keep	NULL
the	NULL
amount	NULL
of	NULL
SV40	NULL
early	NULL
promoter	NULL
sequences	NULL
constant	NULL
,	NULL
since	NULL
EB1	NULL
and	NULL
R	NULL
are	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

Bacterial	NULL
expression	NULL
of	NULL
EBI	NULL
proteins	NULL
.	NULL

A	NULL
cDNA	NULL
containing	NULL
the	NULL
complete	NULL
EB1l-coding	NULL
sequence	NULL
except	NULL
for	NULL
the	NULL
two	NULL
AUGs	NULL
was	NULL
inserted	NULL
in	NULL
the	NULL
EcoRI	NULL
site	NULL
of	NULL
the	NULL
protein	NULL
A	NULL
gene	NULL
fusion	NULL
vector	NULL
pRIT2T	NULL
(	NULL
33	NULL
)	NULL
.	NULL

The	NULL
fusion	NULL
protein	NULL
was	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
HB1O1	NULL
and	NULL
purified	NULL
by	NULL
chromatography	NULL
on	NULL
an	NULL
immunoglobulin	NULL
G-Sepharose	NULL
4B	NULL
column	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
33	NULL
)	NULL
.	NULL

EMSA	NULL
assay	NULL
.	NULL

For	NULL
the	NULL
electrophoresis	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
,	NULL
1	NULL
to	NULL
2	NULL
ug	NULL
of	NULL
protein	NULL
A-EB1l	NULL
was	NULL
incubated	NULL
with	NULL
15,000	NULL
cpm	NULL
of	NULL
an	NULL
87-bp	NULL
*°P-labeled	NULL
DNA	NULL
fragment	NULL
encompassing	NULL
ZRE-B	NULL
from	NULL
positions	NULL
-812	NULL
to	NULL
-899	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Incubations	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
-20	NULL
mM	NULL
HEPES	NULL
(	NULL
N	NULL
-	NULL
2	NULL
-	NULL
hydroxyethylpiperazine	NULL
-	NULL
N	NULL
'	NULL
-	NULL
2	NULL
-	NULL
ethanesulfonic	NULL
acid	NULL
)	NULL
-KOH	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-0.5	NULL
mM	NULL
dithiothreitol-0.5	NULL
mM	NULL
phenyImethyl-sulfonyl	NULL
fluoride-20	NULL
mM	NULL
KCI-20	NULL
%	NULL
glycerol-10	NULL
uM	NULL
zinc	NULL
at	NULL
4°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
loaded	NULL
onto	NULL
a	NULL
4	NULL
%	NULL
polyacryl-amide-0.5x	NULL
TBE	NULL
(	NULL
Tris-borate-EDTA	NULL
)	NULL
gel	NULL
(	NULL
29:1	NULL
cross-linked	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
A-EB1I-ZRE-B	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
the	NULL
noncomplexed	NULL
DNA	NULL
by	NULL
migration	NULL
at	NULL
10	NULL
V/cm	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
experiment	NULL
were	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Dimethyl	NULL
sulfate	NULL
interference	NULL
.	NULL

Two	NULL
hundred	NULL
thousand	NULL
counts	NULL
per	NULL
minute	NULL
of	NULL
the	NULL
87-bp	NULL
DNA	NULL
probe	NULL
was	NULL
methylated	NULL
with	NULL
1	NULL
pl	NULL
of	NULL
dimethyl	NULL
sulfate	NULL
for	NULL
3	NULL
min	NULL
at	NULL
18°C	NULL
.	NULL

The	NULL
methylated	NULL
probe	NULL
was	NULL
then	NULL
incubated	NULL
with	NULL
1	NULL
to	NULL
2	NULL
pg	NULL
of	NULL
protein	NULL
A-EB1	NULL
.	NULL

After	NULL
EMSA	NULL
,	NULL
the	NULL
retarded	NULL
DNA	NULL
probe	NULL
and	NULL
the	NULL
nonretarded	NULL
DNA	NULL
probe	NULL
were	NULL
electroeluted	NULL
and	NULL
incu-	NULL
2812	NULL
GRUFFAT	NULL
ET	NULL
AL	NULL
.	NULL

bated	NULL
in	NULL
100	NULL
pi	NULL
of	NULL
1	NULL
M	NULL
piperidine	NULL
for	NULL
30	NULL
min	NULL
at	NULL
90°C	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
radioactive	NULL
retarded	NULL
and	NULL
nonretarded	NULL
probes	NULL
were	NULL
analyzed	NULL
on	NULL
8	NULL
%	NULL
polyacrylamide	NULL
sequencing	NULL
gels	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

Cell	NULL
culture	NULL
and	NULL
transfections	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
GIBCO	NULL
Laboratories	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
plasmids	NULL
used	NULL
for	NULL
transfection	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
alkaline	NULL
lysis	NULL
method	NULL
and	NULL
purified	NULL
through	NULL
two	NULL
CsCl	NULL
gradients	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
10°	NULL
cells	NULL
per	NULL
100-mm-diameter	NULL
petri	NULL
dish	NULL
24	NULL
h	NULL
before	NULL
transfection	NULL
,	NULL
and	NULL
the	NULL
medium	NULL
was	NULL
changed	NULL
4	NULL
h	NULL
before	NULL
transfection	NULL
.	NULL

Transfections	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
calcium	NULL
precipitate	NULL
method	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
mixed	NULL
with	NULL
the	NULL
appropriate	NULL
DNA	NULL
(	NULL
s	NULL
)	NULL
,	NULL
and	NULL
all	NULL
of	NULL
the	NULL
DNAs	NULL
were	NULL
in	NULL
the	NULL
same	NULL
topological	NULL
state	NULL
,	NULL
as	NULL
assayed	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Usually	NULL
,	NULL
15	NULL
pg	NULL
of	NULL
DNA	NULL
was	NULL
used	NULL
per	NULL
100-mm-diameter	NULL
dish	NULL
,	NULL
including	NULL
the	NULL
following	NULL
:	NULL
1	NULL
wg	NULL
of	NULL
R-expressing	NULL
vector	NULL
or	NULL
2	NULL
ug	NULL
of	NULL
EBl-expressing	NULL
vector	NULL
,	NULL
4	NULL
ug	NULL
of	NULL
reporter	NULL
promoters	NULL
,	NULL
pSVO	NULL
when	NULL
required	NULL
,	NULL
1	NULL
pug	NULL
of	NULL
pSV2B	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
,	NULL
and	NULL
pUC19	NULL
(	NULL
up	NULL
to	NULL
15	NULL
ug	NULL
)	NULL
.	NULL

RNA	NULL
extraction	NULL
and	NULL
S1	NULL
nuclease	NULL
mapping	NULL
.	NULL

The	NULL
cells	NULL
transfected	NULL
with	NULL
plasmids	NULL
carrying	NULL
the	NULL
B-globin	NULL
gene	NULL
were	NULL
lysed	NULL
by	NULL
Nonidet	NULL
P-40	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
nuclei	NULL
were	NULL
pelleted	NULL
,	NULL
and	NULL
RNA	NULL
was	NULL
phenol	NULL
extracted	NULL
from	NULL
the	NULL
cytoplasmic	NULL
fraction	NULL
.	NULL

Ten	NULL
to	NULL
forty	NULL
micrograms	NULL
of	NULL
total	NULL
cytoplasmic	NULL
RNA	NULL
was	NULL
hybridized	NULL
overnight	NULL
at	NULL
30°C	NULL
in	NULL
50	NULL
%	NULL
formamide-0.3	NULL
M	NULL
NaCl-0.01	NULL
M	NULL
Tris	NULL
hydrochloride	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
to	NULL
5	NULL
'	NULL
P-labeled	NULL
synthetic	NULL
single-stranded	NULL
DNA	NULL
probes	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
hybrids	NULL
were	NULL
digested	NULL
for	NULL
2	NULL
h	NULL
at	NULL
20°C	NULL
with	NULL
5	NULL
U	NULL
of	NULL
S1	NULL
nuclease	NULL
per	NULL
10	NULL
ug	NULL
of	NULL
RNA	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
Sl-protected	NULL
DNA	NULL
fragment	NULL
was	NULL
analyzed	NULL
on	NULL
6	NULL
%	NULL
(	NULL
wt/vol	NULL
)	NULL
acrylamide-8.3	NULL
M	NULL
urea	NULL
gels	NULL
.	NULL

RESULTS	NULL
The	NULL
enhancer	NULL
B	NULL
domain	NULL
is	NULL
not	NULL
B-cell	NULL
specific	NULL
and	NULL
responds	NULL
to	NULL
R.	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
DR	NULL
enhancer	NULL
mutants	NULL
obtained	NULL
by	NULL
progressive	NULL
deletion	NULL
from	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
B	NULL
domain	NULL
and	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
SV40	NULL
enhancerless	NULL
early	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
responded	NULL
to	NULL
R	NULL
in	NULL
a	NULL
non-cell-specific	NULL
manner	NULL
(	NULL
5	NULL
)	NULL
.	NULL

One	NULL
R-responsive	NULL
element	NULL
was	NULL
located	NULL
in	NULL
a	NULL
28-bp	NULL
fragment	NULL
containing	NULL
a	NULL
double	NULL
palindrome	NULL
,	NULL
TTGTCCegtGGACAAT	NULL
GTCC	NULL
.	NULL

Since	NULL
recent	NULL
reports	NULL
described	NULL
the	NULL
DR/DL	NULL
enhancer	NULL
as	NULL
EB1	NULL
inducible	NULL
and	NULL
B-cell	NULL
specific	NULL
(	NULL
29	NULL
)	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
confirm	NULL
or	NULL
disconfirm	NULL
this	NULL
statement	NULL
.	NULL

We	NULL
therefore	NULL
determined	NULL
by	NULL
quantitative	NULL
S1	NULL
analysis	NULL
if	NULL
the	NULL
DR	NULL
enhancer	NULL
mutants	NULL
were	NULL
responsive	NULL
to	NULL
R	NULL
in	NULL
HeLa	NULL
cells	NULL
when	NULL
placed	NULL
425	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
rabbit	NULL
B-globin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
and	NULL
if	NULL
the	NULL
palindrome	NULL
GGACAaTGTCC	NULL
was	NULL
an	NULL
R-responsive	NULL
enhan-son	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
B	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
some	NULL
of	NULL
the	NULL
B-domain	NULL
subfragments	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
increased	NULL
(	NULL
about	NULL
threefold	NULL
)	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
in	NULL
plasmid	NULL
pG2	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
cellular	NULL
factors	NULL
participate	NULL
in	NULL
the	NULL
function	NULL
of	NULL
this	NULL
enhancer	NULL
.	NULL

R	NULL
strongly	NULL
stimulated	NULL
the	NULL
expression	NULL
of	NULL
specific	NULL
B-globin	NULL
transcripts	NULL
when	NULL
domain	NULL
B	NULL
was	NULL
inserted	NULL
5	NULL
'	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
sequences	NULL
between	NULL
bp	NULL
-741	NULL
and	NULL
-752	NULL
had	NULL
no	NULL
apparent	NULL
effect	NULL
on	NULL
the	NULL
R	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
deletion	NULL
could	NULL
be	NULL
compensated	NULL
by	NULL
the	NULL
amount	NULL
of	NULL
R	NULL
protein	NULL
expressed	NULL
.	NULL

We	NULL
therefore	NULL
decreased	NULL
by	NULL
a	NULL
factor	NULL
of	NULL
10	NULL
the	NULL
amount	NULL
of	NULL
the	NULL
R-expressing	NULL
vector	NULL
cotransfected	NULL
with	NULL
mutants	NULL
pG2.899/741	NULL
and	NULL
pG2.899/752	NULL
.	NULL

In	NULL
that	NULL
case	NULL
,	NULL
deletion	NULL
of	NULL
sequences	NULL
between	NULL
bp	NULL
-741	NULL
and	NULL
-752	NULL
reduced	NULL
the	NULL
R	NULL
induction	NULL
by	NULL
less	NULL
than	NULL
a	NULL
factor	NULL
of	NULL
two	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
J.	NULL
Viror	NULL
.	NULL

C	NULL
-R	NULL
+R	NULL
ege-	NULL
-*	NULL
=	NULL
&	NULL
&	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
RRE	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Progressive	NULL
BAL	NULL
31	NULL
deletions	NULL
were	NULL
made	NULL
in	NULL
the	NULL
DR	NULL
enhancer	NULL
from	NULL
the	NULL
5°	NULL
end	NULL
or	NULL
from	NULL
the	NULL
3	NULL
'	NULL
end	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
cap	NULL
site	NULL
of	NULL
the	NULL
IR4	NULL
gene	NULL
.	NULL

Numbers	NULL
under	NULL
the	NULL
DNA	NULL
sequence	NULL
indicate	NULL
the	NULL
endpoint	NULL
of	NULL
each	NULL
mutation	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Arrows	NULL
above	NULL
and	NULL
under	NULL
the	NULL
DNA	NULL
sequence	NULL
indicate	NULL
palindromes	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Construction	NULL
of	NULL
plasmids	NULL
pG2.899/741	NULL
,	NULL
pG2.899/752	NULL
,	NULL
pG2.899/775	NULL
,	NULL
pG2.899/812	NULL
,	NULL
pG2.765/737	NULL
,	NULL
and	NULL
pG2.754/	NULL
765	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
the	NULL
remaining	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
mutants	NULL
are	NULL
indicated	NULL
by	NULL
thick	NULL
lines	NULL
,	NULL
and	NULL
the	NULL
numbers	NULL
indicate	NULL
the	NULL
endpoints	NULL
of	NULL
the	NULL
deletion	NULL
for	NULL
each	NULL
mutation	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
mutants	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
either	NULL
alone	NULL
(	NULL
-R	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
7	NULL
)	NULL
or	NULL
with	NULL
an	NULL
R-expressing	NULL
vector	NULL
(	NULL
+R	NULL
,	NULL
lanes	NULL
8	NULL
to	NULL
14	NULL
)	NULL
.	NULL

The	NULL
horizontal	NULL
arrow	NULL
indicates	NULL
the	NULL
specific	NULL
Sl-protected	NULL
DNA	NULL
fragment	NULL
.	NULL

sequences	NULL
between	NULL
bp	NULL
-752	NULL
and	NULL
-775	NULL
impaired	NULL
the	NULL
induction	NULL
of	NULL
B-globin	NULL
transcripts	NULL
by	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
10	NULL
to	NULL
12	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
remaining	NULL
sequences	NULL
in	NULL
mutant	NULL
pG2.765/737	NULL
still	NULL
retained	NULL
a	NULL
low	NULL
,	NULL
but	NULL
clear	NULL
,	NULL
potential	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
R.	NULL
This	NULL
was	NULL
already	NULL
seen	NULL
when	NULL
the	NULL
same	NULL
mutants	NULL
were	NULL
linked	NULL
to	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
(	NULL
5	NULL
)	NULL
and	NULL
suggested	NULL
that	NULL
there	NULL
is	NULL
an	NULL
RRE	NULL
(	NULL
or	NULL
RREs	NULL
)	NULL
located	NULL
between	NULL
position	NULL
-812	NULL
and	NULL
position	NULL
-899	NULL
.	NULL

The	NULL
region	NULL
located	NULL
between	NULL
bp	NULL
-741	NULL
and	NULL
-775	NULL
contains	NULL
the	NULL
two	NULL
partially	NULL
overlapping	NULL
palindromic	NULL
sequences	NULL
TTGTCCCGTGGACAA	NULL
and	NULL
GGACAATGTCC	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

A	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
,	NULL
_	NULL
CTGTGCCITTGTCCCGTGGACAATGT	NULL
CCC	NULL
,	NULL
containing	NULL
these	NULL
two	NULL
palindromes	NULL
was	NULL
cloned	NULL
425	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
plasmid	NULL
pG2.765/737	NULL
;	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
B-globin	NULL
transcripts	NULL
expressed	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
not	NULL
significantly	NULL
influenced	NULL
by	NULL
the	NULL
insertion	NULL
of	NULL
this	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

However	NULL
,	NULL
R	NULL
increased	NULL
the	NULL
amount	NULL
of	NULL
specific	NULL
B-globin	NULL
RNAs	NULL
expressed	NULL
from	NULL
plasmid	NULL
pG2.765/737	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
plasmid	NULL
pG2	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

We	NULL
then	NULL
tested	NULL
whether	NULL
the	NULL
palindrome	NULL
GGACAATGTCC	NULL
was	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
an	NULL
RRE	NULL
.	NULL

The	NULL
answer	NULL
was	NULL
no	NULL
.	NULL

This	NULL
oligonucleotide	NULL
was	NULL
inserted	NULL
5	NULL
'	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
plasmid	NULL
pG2.754/765	NULL
;	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
specific	NULL
B-globin	NULL
transcripts	NULL
expressed	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
not	NULL
influenced	NULL
by	NULL
the	NULL
insertion	NULL
of	NULL
this	NULL
oligonucleotide	NULL
in	NULL
the	NULL
5	NULL
'	NULL
position	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
R	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
B-globin	NULL
transcripts	NULL
expressed	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
in	NULL
plasmid	NULL
pG2.754/765	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
confirmed	NULL
that	NULL
the	NULL
B	NULL
domain	NULL
was	NULL
not	NULL
B-cell	NULL
specific	NULL
but	NULL
instead	NULL
was	NULL
active	NULL
in	NULL
HeLa	NULL
cells	NULL
and	NULL
strongly	NULL
induced	NULL
by	NULL
R.	NULL
The	NULL
R-responsive	NULL
enhancer	NULL
is	NULL
composed	NULL
of	NULL
several	NULL
domains	NULL
responding	NULL
cooperatively	NULL
to	NULL
R.	NULL
Sequences	NULL
located	NULL
between	NULL
positions	NULL
-737	NULL
and	NULL
-765	NULL
and	NULL
containing	NULL
a	NULL
double	NULL
palindromic	NULL
sequence	NULL
transmit	NULL
the	NULL
activation	NULL
by	NULL
R	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
,	NULL
but	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
is	NULL
lower	NULL
than	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
by	NULL
R	NULL
through	NULL
the	NULL
B	NULL
domain	NULL
by	NULL
a	NULL
factor	NULL
of	NULL
about	NULL
four	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
one	NULL
palindrome	NULL
does	NULL
not	NULL
respond	NULL
to	NULL
R.	NULL
However	NULL
,	NULL
mutant	NULL
pG2.899/752	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
contains	NULL
one	NULL
palindrome	NULL
and	NULL
downstream	NULL
sequences	NULL
but	NULL
responds	NULL
to	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
although	NULL
mutant	NULL
pG2.899/775	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
does	NULL
not	NULL
respond	NULL
to	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
mutant	NULL
pG2.737/805	NULL
,	NULL
which	NULL
contains	NULL
sequences	NULL
located	NULL
between	NULL
positions	NULL
-737	NULL
and	NULL
-805	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
contains	NULL
a	NULL
full	NULL
RRE	NULL
.	NULL

Therefore	NULL
,	NULL
sequences	NULL
between	NULL
positions	NULL
-741	NULL
and	NULL
-805	NULL
must	NULL
contain	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
characterize	NULL
further	NULL
this	NULL
putative	NULL
R-responsive	NULL
region	NULL
,	NULL
several	NULL
double-stranded	NULL
oligonucleotides	NULL
that	NULL
cover	NULL
sequences	NULL
between	NULL
positions	NULL
-737	NULL
and	NULL
-805	NULL
have	NULL
been	NULL
synthesized	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

These	NULL
oligonucleotides	NULL
have	NULL
been	NULL
ligated	NULL
425	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
plasmids	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
response	NULL
to	NULL
R	NULL
was	NULL
evaluated	NULL
by	NULL
S1	NULL
nuclease	NULL
digestion	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

Quantitation	NULL
was	NULL
done	NULL
on	NULL
three	NULL
different	NULL
transfections	NULL
(	NULL
one	NULL
typical	NULL
experiment	NULL
is	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
by	NULL
cutting	NULL
the	NULL
specific	NULL
S1-protected	NULL
radioactive	NULL
bands	NULL
from	NULL
the	NULL
gels	NULL
and	NULL
by	NULL
counting	NULL
the	NULL
radioactivity	NULL
.	NULL

The	NULL
results	NULL
were	NULL
corrected	NULL
as	NULL
follows	NULL
:	NULL
(	NULL
i	NULL
)	NULL
according	NULL
to	NULL
the	NULL
efficiency	NULL
of	NULL
transfection	NULL
as	NULL
evaluated	NULL
by	NULL
counting	NULL
the	NULL
radioactivity	NULL
present	NULL
in	NULL
Sl-protected	NULL
bands	NULL
corresponding	NULL
to	NULL
specific	NULL
SV40	NULL
early	NULL
RNAs	NULL
expressed	NULL
from	NULL
plasmid	NULL
pSV2§B	NULL
(	NULL
2	NULL
)	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
according	NULL
to	NULL
the	NULL
activities	NULL
of	NULL
the	NULL
different	NULL
constructions	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
R.	NULL
The	NULL
results	NULL
of	NULL
quantification	NULL
(	NULL
average	NULL
)	NULL
are	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

The	NULL
main	NULL
conclusions	NULL
from	NULL
these	NULL
experiments	NULL
are	NULL
the	NULL
following	NULL
.	NULL

As	NULL
already	NULL
shown	NULL
,	NULL
the	NULL
enhancer	NULL
B	NULL
domain	NULL
between	NULL
positions	NULL
-899	NULL
and	NULL
-752	NULL
can	NULL
constitutively	NULL
increase	NULL
about	NULL
threefold	NULL
the	NULL
B-globin	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
compare	NULL
lanes	NULL
9	NULL
and	NULL
1	NULL
)	NULL
.	NULL

Sequences	NULL
between	NULL
positions	NULL
-737	NULL
and	NULL
-765	NULL
contain	NULL
a	NULL
protoenhancer	NULL
that	NULL
has	NULL
15	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
of	NULL
the	NULL
R-induced	NULL
enhancer	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
11	NULL
)	NULL
.	NULL

This	NULL
protoenhancer	NULL
can	NULL
not	NULL
be	NULL
reduced	NULL
to	NULL
a	NULL
shorter	NULL
element	NULL
,	NULL
since	NULL
no	NULL
subregion	NULL
responded	NULL
to	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
protoenhancer	NULL
activity	NULL
increased	NULL
to	NULL
44	NULL
%	NULL
of	NULL
the	NULL
R-induced	NULL
enhancer	NULL
activity	NULL
when	NULL
it	NULL
was	NULL
linked	NULL
to	NULL
sequences	NULL
between	NULL
positions	NULL
-765	NULL
and	NULL
-783	NULL
and	NULL
extended	NULL
from	NULL
positions	NULL
-737	NULL
to	NULL
-783	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
DNA	NULL
sequence	NULL
between	NULL
positions	NULL
-761	NULL
and	NULL
-783	NULL
had	NULL
no	NULL
constitutive	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
was	NULL
not	NULL
responsive	NULL
to	NULL
R	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
pG2	NULL
itself	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
compare	NULL
lane	NULL
3	NULL
with	NULL
lane	NULL
12	NULL
and	NULL
lane	NULL
9	NULL
with	NULL
lane	NULL
18	NULL
)	NULL
.	NULL

These	NULL
two	NULL
regions	NULL
then	NULL
seemed	NULL
to	NULL
have	NULL
more	NULL
than	NULL
an	NULL
additive	NULL
effect	NULL
.	NULL

However	NULL
,	NULL
even	NULL
when	NULL
these	NULL
two	NULL
regions	NULL
were	NULL
linked	NULL
together	NULL
,	NULL
they	NULL
only	NULL
ORL	NULL
,	NULL
,	NULL
ENHANCER	NULL
TRANSACTIVATION	NULL
2813	NULL
-~	NULL
WW	NULL
UIHIII	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
RRE	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Synthetic	NULL
double-stranded	NULL
oligonucleotides	NULL
used	NULL
to	NULL
characterize	NULL
the	NULL
RRE	NULL
are	NULL
listed	NULL
under	NULL
the	NULL
genomic	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
double-stranded	NULL
oligonucleotides	NULL
were	NULL
ligated	NULL
to	NULL
plasmid	NULL
pG2	NULL
,	NULL
and	NULL
the	NULL
relative	NULL
responsiveness	NULL
to	NULL
R	NULL
of	NULL
the	NULL
resulting	NULL
recombinant	NULL
genes	NULL
was	NULL
determined	NULL
by	NULL
quantitative	NULL
S1	NULL
analysis	NULL
as	NULL
described	NULL
in	NULL
Results	NULL
,	NULL
with	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Display	NULL
of	NULL
one	NULL
typical	NULL
quantitative	NULL
S1	NULL
analysis	NULL
of	NULL
B-globin	NULL
RNA	NULL
expressed	NULL
from	NULL
some	NULL
of	NULL
the	NULL
plasmids	NULL
described	NULL
above	NULL
.	NULL

The	NULL
plasmids	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
without	NULL
(	NULL
-R	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
9	NULL
)	NULL
or	NULL
with	NULL
(	NULL
+R	NULL
,	NULL
lanes	NULL
10	NULL
to	NULL
18	NULL
)	NULL
a	NULL
vector	NULL
expressing	NULL
R.	NULL
The	NULL
single-stranded	NULL
DNA	NULL
probe	NULL
is	NULL
the	NULL
one	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Quantitative	NULL
S1	NULL
nuclease	NULL
analysis	NULL
of	NULL
RNA	NULL
expressed	NULL
from	NULL
plasmid	NULL
pSV2	NULL
$	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

The	NULL
S1	NULL
probe	NULL
sequence	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

The	NULL
number	NULL
above	NULL
each	NULL
lane	NULL
corresponds	NULL
to	NULL
the	NULL
samples	NULL
presented	NULL
in	NULL
panel	NULL
C.	NULL
accounted	NULL
for	NULL
about	NULL
52	NULL
%	NULL
of	NULL
the	NULL
R-dependent	NULL
enhancer	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
another	NULL
region	NULL
is	NULL
required	NULL
in	NULL
order	NULL
to	NULL
reach	NULL
100	NULL
%	NULL
of	NULL
activity	NULL
.	NULL

This	NULL
region	NULL
is	NULL
probably	NULL
located	NULL
between	NULL
positions	NULL
-789	NULL
and	NULL
-810	NULL
,	NULL
since	NULL
mutant	NULL
pG2.737/	NULL
805	NULL
has	NULL
full	NULL
enhancer	NULL
activity	NULL
as	NULL
compared	NULL
with	NULL
mutant	NULL
pG2.899/752	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
compare	NULL
lanes	NULL
6	NULL
and	NULL
10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
region	NULL
is	NULL
not	NULL
responsive	NULL
to	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
mutant	NULL
pG2.810/789	NULL
)	NULL
.	NULL

We	NULL
could	NULL
therefore	NULL
conclude	NULL
that	NULL
one	NULL
RRE	NULL
is	NULL
probably	NULL
composed	NULL
of	NULL
three	NULL
protoenhancers	NULL
(	NULL
15	NULL
)	NULL
that	NULL
could	NULL
act	NULL
cooperatively	NULL
to	NULL
mediate	NULL
the	NULL
response	NULL
to	NULL
R.	NULL
The	NULL
EB1-binding	NULL
site	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
RRE	NULL
is	NULL
not	NULL
an	NULL
EB1-inducible	NULL
enhanson	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
RRE	NULL
described	NULL
above	NULL
was	NULL
in	NULL
fact	NULL
a	NULL
B-cell-specific	NULL
EB1l-responsive	NULL
element	NULL
(	NULL
29	NULL
)	NULL
that	NULL
could	NULL
respond	NULL
synergistically	NULL
to	NULL
EB1	NULL
and	NULL
R	NULL
(	NULL
11	NULL
)	NULL
.	NULL

This	NULL
is	NULL
clearly	NULL
not	NULL
the	NULL
case	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
results	NULL
presented	NULL
above	NULL
and	NULL
by	NULL
previously	NULL
published	NULL
results	NULL
from	NULL
our	NULL
laboratory	NULL
(	NULL
5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
if	NULL
there	NULL
were	NULL
an	NULL
EB1-binding	NULL
site	NULL
located	NULL
close	NULL
to	NULL
the	NULL
RRE	NULL
,	NULL
EB1	NULL
might	NULL
contribute	NULL
2814	NULL
GRUFFAT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
J.	NULL
ViroL	NULL
.	NULL

PROBE	NULL
-23	NULL
(	NULL
ng	NULL
)	NULL
11	NULL
11	NULL
11	NULL
H1	NULL
11	NULL
11	NULL
11	NULL
11	NULL
11	NULL
11	NULL
COMPETITORS	NULL
(	NULL
MASS	NULL
EXCESS	NULL
)	NULL
ZRE-B	NULL
2	NULL
S	NULL
10	NULL
ZRE-Z	NULL
2	NULL
5	NULL
10	NULL
ZRE-22	NULL
10	NULL
¢	NULL
pA	NULL
6ul	NULL
*	NULL
=	NULL
PROTEINS	NULL
-	NULL
.	NULL

-	NULL
outs	NULL
``	NULL
EBI	NULL
3ul	NULL
6ul	NULL
6ul	NULL
6u	NULL
!	NULL

l	NULL
6ul	NULL
6ul	NULL
6ul	NULL
6ul	NULL
6p	NULL
!	NULL

luce	NULL
withs	NULL
~	NULL
oo	NULL
aes	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
.	NULL

8	NULL
9	NULL
10	NULL
--	NULL
“	NULL
x	NULL
heme	NULL
:	NULL
is	NULL
«	NULL
ame	NULL
cao	NULL
wil	NULL
care	NULL
«	NULL
e	NULL
--	NULL
:	NULL
ws	NULL
.	NULL

nes	NULL
0	NULL
Cae	NULL
d	NULL
|	NULL
um	NULL
|	NULL
sons	NULL
HB	NULL
o-	NULL
.	NULL

dats	NULL
-	NULL
wan	NULL
#	NULL
==	NULL
«	NULL
am	NULL
wen	NULL
Gw	NULL
me	NULL
aie	NULL
c	NULL
»	NULL
#	NULL
.L	NULL
.	NULL

,	NULL
~	NULL
cme	NULL
»	NULL
se	NULL
U	NULL
«	NULL
wo	NULL
-	NULL
``	NULL
mam	NULL
w	NULL
»	NULL
lib	NULL
wan	NULL
fa	NULL
«	NULL
im	NULL
~	NULL
re	NULL
fad	NULL
«	NULL
am	NULL
IRE-Z	NULL
6C	NULL
rmsccachGCATT	NULL
am	NULL
CGT	NULL
|A	NULL
cGGTGITCCGT	NULL
AA	NULL
w*	NULL
<	NULL
e	NULL
IRE-22	NULL
GCATGATAGACJAGGCATT	NULL
CGT	NULL
TAT	NULL
TCCGTAA	NULL
IEE-B	NULL
AGATCTCCTGCCTCACCATGACACACTccocos	NULL
@	NULL
a	NULL
»	NULL
..	NULL
T	NULL
(	NULL
TAGAGGAKGGAGYGGTACIGVUQTGQAGGCGCC	NULL
«	NULL
<	NULL
»	NULL
812	NULL
899	NULL
Q1	NULL
S	NULL
GCCCCCGTTGCTCGCCTTGCCTGCCTCACCNLT	NULL
3°	NULL
CGGGGGCAACGAGCGGAACGGACGGAGTGGTACTGTGTG	NULL
L	NULL
#	NULL
w	NULL
_s	NULL
x	NULL
he-	NULL
;	NULL
GACACACITAAGCCCCTGCTAATCCATGAGCCCCGCCTTTAGGAAGCACCACGTCCC	NULL
ATTCGGGGACGATTAGGTACTCGGGGCGGAAATCCT	NULL
TCGTGGTGCAGGG	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
EBl-binding	NULL
site	NULL
by	NULL
DNA	NULL
competition	NULL
and	NULL
by	NULL
methylation	NULL
interference	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DNA-binding	NULL
assay	NULL
of	NULL
EB1	NULL
and	NULL
competitions	NULL
.	NULL

Probe	NULL
-23	NULL
was	NULL
incubated	NULL
with	NULL
purified	NULL
protein	NULL
A	NULL
(	NULL
pA	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
the	NULL
protein	NULL
A-EB1	NULL
fusion	NULL
protein	NULL
(	NULL
EB1	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Competitor	NULL
DNAs	NULL
were	NULL
added	NULL
at	NULL
mass	NULL
ratios	NULL
of	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
amount	NULL
of	NULL
labeled	NULL
probe	NULL
present	NULL
.	NULL

Specific	NULL
complexes	NULL
are	NULL
indicated	NULL
by	NULL
horizontal	NULL
arrows	NULL
.	NULL

The	NULL
two	NULL
lowest	NULL
complexes	NULL
were	NULL
generated	NULL
by	NULL
degraded	NULL
protein	NULL
A-EB1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Fine	NULL
mapping	NULL
of	NULL
EB1-binding	NULL
sites	NULL
by	NULL
methylation	NULL
interference	NULL
.	NULL

DNA-binding	NULL
assays	NULL
were	NULL
performed	NULL
under	NULL
standard	NULL
conditions	NULL
except	NULL
that	NULL
probe	NULL
-23	NULL
(	NULL
5	NULL
'	NULL
end	NULL
labeled	NULL
either	NULL
on	NULL
the	NULL
coding	NULL
[	NULL
5	NULL
'	NULL
]	NULL
or	NULL
the	NULL
noncoding	NULL
[	NULL
3	NULL
'	NULL
]	NULL
strand	NULL
)	NULL
was	NULL
treated	NULL
with	NULL
dimethyl	NULL
sulfate	NULL
before	NULL
incubation	NULL
with	NULL
the	NULL
protein	NULL
A-EB1	NULL
.	NULL

G+A	NULL
is	NULL
a	NULL
Maxam	NULL
and	NULL
Gilbert	NULL
sequence	NULL
ladder	NULL
.	NULL

NR	NULL
is	NULL
the	NULL
nonretarded	NULL
probe	NULL
,	NULL
and	NULL
R	NULL
is	NULL
the	NULL
slower	NULL
retarded	NULL
complex	NULL
.	NULL

Asterisks	NULL
indicate	NULL
those	NULL
G	NULL
residues	NULL
whose	NULL
methylation	NULL
strongly	NULL
prevents	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
;	NULL
the	NULL
open	NULL
circle	NULL
indicates	NULL
the	NULL
residue	NULL
which	NULL
is	NULL
weakly	NULL
involved	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Sequences	NULL
of	NULL
the	NULL
probes	NULL
used	NULL
for	NULL
formation	NULL
of	NULL
protein-DNA	NULL
complexes	NULL
and	NULL
for	NULL
competition	NULL
experiments	NULL
.	NULL

The	NULL
EB1-binding	NULL
site	NULL
of	NULL
each	NULL
sequence	NULL
is	NULL
indicated	NULL
by	NULL
a	NULL
box	NULL
.	NULL

ZRE-Z2	NULL
is	NULL
a	NULL
mutated	NULL
version	NULL
of	NULL
ZRE-Z	NULL
,	NULL
and	NULL
the	NULL
bases	NULL
changed	NULL
are	NULL
indicated	NULL
by	NULL
a	NULL
thick	NULL
line	NULL
above	NULL
the	NULL
ZRE-Z2	NULL
sequence	NULL
.	NULL

The	NULL
G	NULL
residues	NULL
involved	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
specific	NULL
nucleoprotein	NULL
complexes	NULL
on	NULL
probe	NULL
-23	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
*	NULL
,	NULL
@	NULL
)	NULL
.	NULL

to	NULL
the	NULL
enhancer	NULL
activity	NULL
.	NULL

There	NULL
is	NULL
indeed	NULL
an	NULL
EB1-binding	NULL
site	NULL
(	NULL
ZRE-B	NULL
;	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
RRE	NULL
located	NULL
between	NULL
positions	NULL
-843	NULL
and	NULL
-851	NULL
.	NULL

An	NULL
EB1l-protein	NULL
A	NULL
hybrid	NULL
binds	NULL
to	NULL
a	NULL
labeled	NULL
DNA	NULL
fragment	NULL
carrying	NULL
ZRE-B	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
,	NULL
and	NULL
the	NULL
binding	NULL
is	NULL
specific	NULL
,	NULL
since	NULL
it	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotides	NULL
carrying	NULL
ZRE-B	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
or	NULL
ZRE-Z	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
9	NULL
;	NULL
ZRE-Z	NULL
is	NULL
an	NULL
EBl-binding	NULL
site	NULL
present	NULL
in	NULL
the	NULL
BZLF1	NULL
promoter	NULL
[	NULL
28	NULL
]	NULL
)	NULL
but	NULL
was	NULL
not	NULL
competed	NULL
out	NULL
by	NULL
ZRE-Z2	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
which	NULL
does	NULL
not	NULL
bind	NULL
EB1	NULL
(	NULL
G.	NULL
Urier	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Dimethyl	NULL
sulfate	NULL
interference	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
demonstrated	NULL
that	NULL
this	NULL
EBl-protein	NULL
A	NULL
hybrid	NULL
interacted	NULL
specifically	NULL
with	NULL
the	NULL
TGACACAC	NULL
motif	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
this	NULL
EBl-binding	NULL
site	NULL
was	NULL
a	NULL
functional	NULL
enhancer	NULL
element	NULL
and	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
R	NULL
response	NULL
,	NULL
plasmids	NULL
pG2	NULL
,	NULL
pG2.899/752	NULL
,	NULL
pG2.899/812	NULL
,	NULL
and	NULL
pG2.737/805	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
either	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
an	NULL
EB1-	NULL
and/or	NULL
an	NULL
R-expressing	NULL
vector	NULL
.	NULL

In	NULL
these	NULL
plasmids	NULL
,	NULL
ZRE-B	NULL
is	NULL
localized	NULL
about	NULL
500	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
initiation	NULL
site	NULL
.	NULL

This	NULL
position	NULL
can	NULL
be	NULL
considered	NULL
to	NULL
be	NULL
far	NULL
enough	NULL
from	NULL
the	NULL
B-globin	NULL
initiation	NULL
site	NULL
to	NULL
test	NULL
its	NULL
enhancer	NULL
properties	NULL
in	NULL
a	NULL
very	NULL
general	NULL
sense	NULL
,	NULL
since	NULL
we	NULL
have	NULL
reported	NULL
that	NULL
two	NULL
other	NULL
ZREs	NULL
could	NULL
render	NULL
the	NULL
B-globin	NULL
promoter	NULL
responsive	NULL
to	NULL
EB1	NULL
when	NULL
localized	NULL
at	NULL
position	NULL
-100	NULL
upstream	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
but	NULL
lost	NULL
their	NULL
activity	NULL
when	NULL
localized	NULL
at	NULL
position	NULL
-425	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Plasmid	NULL
pSV2B	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
and	NULL
the	NULL
quantity	NULL
of	NULL
SV40-B-globin	NULL
transcripts	NULL
was	NULL
almost	NULL
equal	NULL
in	NULL
every	NULL
transfection	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

As	NULL
detected	NULL
by	NULL
quantitative	NULL
S1	NULL
analysis	NULL
,	NULL
the	NULL
B-globin	NULL
promoter	NULL
in	NULL
plasmid	NULL
pG2	NULL
had	NULL
a	NULL
weak	NULL
basal	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
already	NULL
observed	NULL
above	NULL
,	NULL
the	NULL
B-globin	NULL
promoter	NULL
activity	NULL
in	NULL
plasmid	NULL
pG2	NULL
was	NULL
increased	NULL
by	NULL
twofold	NULL
when	NULL
the	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
an	NULL
R-expressing	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
or	NULL
with	NULL
EB1l-	NULL
and	NULL
R-expressing	NULL
vectors	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
basal	NULL
activity	NULL
was	NULL
not	NULL
influ-	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
-544	NULL
~899	NULL
|um=	NULL
ZRE	NULL
-Ben	NULL
|	NULL
-	NULL
752	NULL
p62.899/752	NULL
-899	NULL
|===ZRE-B==	NULL
812	NULL
pG2.899/812	NULL
~737	NULL
|	NULL
-8	NULL
05	NULL
+1	NULL
rabbit	NULL
B-globin	NULL
-425	NULL
B	NULL
p62	NULL
p62	NULL
899/752	NULL
pG2.737/805	NULL
pG2899/812	NULL
/	NULL
®	NULL
EBigsill/	NULL
r	NULL
esigsil/	NULL
r	NULL
r	NULL
eBigs	NULL
:	NULL
re	NULL
e	NULL
%	NULL
7	NULL
R	NULL
r	NULL
rR	NULL
r	NULL
n	NULL
I	NULL
2	NULL
$	NULL
4	NULL
5	NULL
6	NULL
I	NULL
B	NULL
9	NULL
Io	NULL
11	NULL
12	NULL
1s	NULL
14	NULL
is	NULL
is	NULL
%	NULL
a	NULL
P=	NULL
»	NULL
ie	NULL
o	NULL
fl	NULL
hd	NULL
#	NULL
43.	NULL
,	NULL
«	NULL
»	NULL
42	NULL
&	NULL
pet	NULL
ates	NULL
C	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
1011121314	NULL
1516	NULL
$	NULL
7	NULL
was	NULL
as	NULL
sm	NULL
«	NULL
<	NULL
s	NULL
CP	NULL
»	NULL
$	NULL
3	NULL
55	NULL
a	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

ZRE-B	NULL
is	NULL
not	NULL
functional	NULL
when	NULL
localized	NULL
as	NULL
an	NULL
enhancer	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Construction	NULL
of	NULL
plasmids	NULL
pG2.899/752	NULL
,	NULL
pG2.737/805	NULL
,	NULL
and	NULL
pG2.899/812	NULL
.	NULL

The	NULL
numbers	NULL
above	NULL
the	NULL
thick	NULL
lanes	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
ZRE-B	NULL
and	NULL
RRE1	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
B-globin	NULL
gene	NULL
initiation	NULL
site	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitative	NULL
S1	NULL
nuclease	NULL
analysis	NULL
of	NULL
RNAs	NULL
expressed	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
various	NULL
DNA	NULL
templates	NULL
indicated	NULL
in	NULL
the	NULL
upper	NULL
part	NULL
of	NULL
the	NULL
figure	NULL
either	NULL
alone	NULL
(	NULL
/	NULL
)	NULL
,	NULL
with	NULL
an	NULL
R-expressing	NULL
vector	NULL
(	NULL
R	NULL
)	NULL
,	NULL
with	NULL
an	NULL
EBl-expressing	NULL
vector	NULL
(	NULL
EB1	NULL
)	NULL
,	NULL
or	NULL
with	NULL
an	NULL
R-expressing	NULL
vector	NULL
plus	NULL
an	NULL
EBl-expressing	NULL
vector	NULL
(	NULL
EB1	NULL
+	NULL
R	NULL
)	NULL
.	NULL

M	NULL
,	NULL
Molecular	NULL
weight	NULL
mark-ers	NULL
;	NULL
P	NULL
,	NULL
full-size	NULL
protected	NULL
probe	NULL
.	NULL

The	NULL
specific	NULL
B-globin	NULL
initiation	NULL
sites	NULL
are	NULL
indicated	NULL
by	NULL
horizontal	NULL
arrows	NULL
and	NULL
the	NULL
numbers	NULL
42	NULL
and	NULL
43	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Quantitative	NULL
S1	NULL
nuclease	NULL
mapping	NULL
of	NULL
SV40	NULL
RNAs	NULL
expressed	NULL
from	NULL
plasmid	NULL
pSV2B	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

The	NULL
numbers	NULL
over	NULL
each	NULL
lane	NULL
correspond	NULL
to	NULL
the	NULL
samples	NULL
presented	NULL
in	NULL
panel	NULL
B.	NULL
Horizontal	NULL
arrows	NULL
indicate	NULL
SV40-specific	NULL
initiation	NULL
sites	NULL
.	NULL

enced	NULL
by	NULL
EB1	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Plasmid	NULL
pG2.899/752	NULL
,	NULL
which	NULL
carried	NULL
both	NULL
RREs	NULL
and	NULL
the	NULL
EBl-binding	NULL
site	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
-globin	NULL
promoter	NULL
,	NULL
had	NULL
a	NULL
higher	NULL
basal	NULL
activity	NULL
because	NULL
of	NULL
the	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
;	NULL
as	NULL
expected	NULL
,	NULL
this	NULL
basal	NULL
activity	NULL
was	NULL
strongly	NULL
activated	NULL
by	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
but	NULL
not	NULL
by	NULL
EB1	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
there	NULL
was	NULL
no	NULL
additive	NULL
effect	NULL
with	NULL
EB1	NULL
plus	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
R	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
pointed	NULL
out	NULL
that	NULL
EB1	NULL
seems	NULL
to	NULL
have	NULL
an	NULL
effect	NULL
on	NULL
plasmid	NULL
pG2.899/752	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
compare	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
,	NULL
but	NULL
this	NULL
effect	NULL
is	NULL
also	NULL
found	NULL
in	NULL
the	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
7	NULL
)	NULL
.	NULL

Plasmid	NULL
pG2.737/805	NULL
,	NULL
which	NULL
carried	NULL
only	NULL
the	NULL
RRE	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
,	NULL
had	NULL
a	NULL
basal	NULL
activity	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
pG2.899/752	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

This	NULL
basal	NULL
activity	NULL
was	NULL
strongly	NULL
activated	NULL
by	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
plasmid	NULL
pG2.899/752	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
EB1	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
in	NULL
plasmid	NULL
pG2.737/805	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
and	NULL
there	NULL
was	NULL
no	NULL
additional	NULL
effect	NULL
with	NULL
EB1	NULL
plus	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

Plasmid	NULL
pG2.899/812	NULL
contained	NULL
only	NULL
the	NULL
EB1l-binding	NULL
site	NULL
located	NULL
5	NULL
'	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
.	NULL

The	NULL
B-globin	NULL
promoter	NULL
in	NULL
this	NULL
plasmid	NULL
had	NULL
a	NULL
weak	NULL
basal	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
,	NULL
and	NULL
this	NULL
basal	NULL
activity	NULL
was	NULL
significantly	NULL
altered	NULL
by	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
14	NULL
)	NULL
but	NULL
not	NULL
by	NULL
EB1	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
15	NULL
)	NULL
;	NULL
once	NULL
again	NULL
,	NULL
there	NULL
was	NULL
no	NULL
additive	NULL
effect	NULL
with	NULL
EB1	NULL
plus	NULL
R	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
16	NULL
)	NULL
.	NULL

These	NULL
last	NULL
results	NULL
clearly	NULL
demonstrated	NULL
that	NULL
ZRE-B	NULL
was	NULL
not	NULL
signifi-	NULL
ORL	NULL
,	NULL
,	NULL
ENHANCER	NULL
TRANSACTIVATION	NULL
2815	NULL
cantly	NULL
active	NULL
when	NULL
localized	NULL
more	NULL
than	NULL
425	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
and	NULL
was	NULL
not	NULL
part	NULL
of	NULL
the	NULL
R-inducible	NULL
enhancer	NULL
.	NULL

Moreover	NULL
,	NULL
no	NULL
synergy	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
a	NULL
more	NULL
than	NULL
multiplicative	NULL
effect	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
,	NULL
could	NULL
be	NULL
detected	NULL
.	NULL

These	NULL
results	NULL
also	NULL
show	NULL
that	NULL
EBV	NULL
sequences	NULL
located	NULL
between	NULL
positions	NULL
-805	NULL
and	NULL
-858	NULL
contain	NULL
an	NULL
RRE	NULL
(	NULL
or	NULL
RREs	NULL
)	NULL
and	NULL
should	NULL
be	NULL
considered	NULL
as	NULL
part	NULL
of	NULL
the	NULL
R-inducible	NULL
enhancer	NULL
.	NULL

ZRE-B	NULL
is	NULL
active	NULL
when	NULL
located	NULL
close	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
in	NULL
which	NULL
case	NULL
R	NULL
and	NULL
EB1	NULL
effects	NULL
can	NULL
be	NULL
additive	NULL
.	NULL

From	NULL
the	NULL
results	NULL
presented	NULL
above	NULL
,	NULL
it	NULL
was	NULL
not	NULL
possible	NULL
to	NULL
detect	NULL
a	NULL
synergy	NULL
between	NULL
EBl	NULL
and	NULL
R.	NULL
However	NULL
,	NULL
to	NULL
observe	NULL
synergy	NULL
,	NULL
one	NULL
might	NULL
have	NULL
to	NULL
reduce	NULL
the	NULL
R	NULL
activation	NULL
and	NULL
move	NULL
ZRE-B	NULL
very	NULL
close	NULL
to	NULL
the	NULL
B-globin	NULL
TATA	NULL
box	NULL
,	NULL
as	NULL
is	NULL
the	NULL
situation	NULL
in	NULL
the	NULL
putative	NULL
EA-R	NULL
promoter	NULL
(	NULL
29	NULL
)	NULL
,	NULL
on	NULL
which	NULL
synergy	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
is	NULL
detected	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Reducing	NULL
R	NULL
activation	NULL
should	NULL
be	NULL
possible	NULL
either	NULL
by	NULL
decreasing	NULL
the	NULL
amount	NULL
of	NULL
R-expressing	NULL
vector	NULL
or	NULL
by	NULL
deleting	NULL
all	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
upstream	NULL
elements	NULL
,	NULL
keeping	NULL
only	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

We	NULL
therefore	NULL
placed	NULL
the	NULL
B	NULL
domain	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
initiation	NULL
sites	NULL
,	NULL
and	NULL
ZRE-B	NULL
was	NULL
then	NULL
located	NULL
at	NULL
positions	NULL
-549	NULL
(	NULL
plasmid	NULL
pG2.899/741	NULL
)	NULL
,	NULL
-106	NULL
(	NULL
plasmid	NULL
pG3.741/861	NULL
)	NULL
,	NULL
and	NULL
-113	NULL
(	NULL
plasmid	NULL
pG4.741/899	NULL
)	NULL
;	NULL
in	NULL
this	NULL
last	NULL
construction	NULL
,	NULL
the	NULL
B-globin	NULL
promoter	NULL
upstream	NULL
elements	NULL
were	NULL
deleted	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
through	NULL
C	NULL
)	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
responses	NULL
to	NULL
increasing	NULL
amounts	NULL
of	NULL
EB1	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
R	NULL
,	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
R	NULL
plus	NULL
constant	NULL
amounts	NULL
of	NULL
EBl	NULL
were	NULL
evaluated	NULL
.	NULL

The	NULL
autoradiographs	NULL
presented	NULL
were	NULL
overexposed	NULL
in	NULL
order	NULL
to	NULL
detect	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
.	NULL

However	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
EB1	NULL
,	NULL
R	NULL
,	NULL
and	NULL
EB1	NULL
plus	NULL
R	NULL
were	NULL
quanti-tated	NULL
,	NULL
whenever	NULL
possible	NULL
,	NULL
by	NULL
the	NULL
scanning	NULL
of	NULL
autoradiographs	NULL
exposed	NULL
for	NULL
a	NULL
short	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
see	NULL
inserts	NULL
in	NULL
each	NULL
panel	NULL
)	NULL
.	NULL

Plasmid	NULL
PSV2B	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
,	NULL
and	NULL
quantification	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
specifically	NULL
initiated	NULL
SV40-B-globin	NULL
RNAs	NULL
is	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
(	NULL
lanes	NULL
labeled	NULL
*	NULL
``	NULL
pSV2	NULL
$	NULL
B	NULL
internal	NULL
control	NULL
specific	NULL
transcription	NULL
``	NULL
or	NULL
``	NULL
pSV2B	NULL
``	NULL
)	NULL
.	NULL

The	NULL
B-globin	NULL
promoter	NULL
basal	NULL
activity	NULL
in	NULL
plasmid	NULL
pG2.899/	NULL
741	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
was	NULL
not	NULL
increased	NULL
by	NULL
increasing	NULL
amounts	NULL
of	NULL
EBl-expressing	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
Sl-protected	NULL
radioactivity	NULL
seemed	NULL
to	NULL
be	NULL
higher	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EB1	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
than	NULL
with	NULL
an	NULL
increasing	NULL
amount	NULL
of	NULL
EBI1	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
is	NULL
due	NULL
to	NULL
variations	NULL
in	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
radioactive	NULL
bands	NULL
.	NULL

This	NULL
basal	NULL
activity	NULL
increased	NULL
proportionally	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
R-expressing	NULL
vector	NULL
from	NULL
20	NULL
to	NULL
500	NULL
ng	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
and	NULL
then	NULL
reached	NULL
a	NULL
plateau	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
cotransfecting	NULL
a	NULL
constant	NULL
amount	NULL
of	NULL
EBl-expressing	NULL
vector	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
R-expressing	NULL
vectors	NULL
did	NULL
not	NULL
have	NULL
even	NULL
an	NULL
additive	NULL
effect	NULL
on	NULL
the	NULL
level	NULL
of	NULL
R	NULL
transactivation	NULL
,	NULL
except	NULL
maybe	NULL
at	NULL
low	NULL
R	NULL
concentration	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
9	NULL
to	NULL
12	NULL
)	NULL
.	NULL

When	NULL
ZRE-B	NULL
was	NULL
localized	NULL
at	NULL
position	NULL
-106	NULL
(	NULL
plasmid	NULL
pG3.741/861	NULL
;	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
,	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
was	NULL
detectably	NULL
increased	NULL
by	NULL
increasing	NULL
amounts	NULL
of	NULL
EBl	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

This	NULL
showed	NULL
that	NULL
ZRE-B	NULL
becomes	NULL
active	NULL
when	NULL
located	NULL
closer	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

The	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
increased	NULL
proportionally	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
R-expressing	NULL
vector	NULL
from	NULL
20	NULL
to	NULL
100	NULL
ng	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
and	NULL
then	NULL
reached	NULL
a	NULL
plateau	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
an	NULL
additive	NULL
effect	NULL
between	NULL
EBl	NULL
and	NULL
R	NULL
was	NULL
detected	NULL
when	NULL
2	NULL
ug	NULL
of	NULL
EBl-expressing	NULL
vector	NULL
were	NULL
cotransfected	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
R-expressing	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

At	NULL
higher	NULL
R-expressing	NULL
vector	NULL
concentrations	NULL
,	NULL
no	NULL
additive	NULL
effect	NULL
of	NULL
EB1	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lanes	NULL
10	NULL
to	NULL
12	NULL
)	NULL
was	NULL
observed	NULL
.	NULL

2816	NULL
GRUFFAT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
<	NULL
-	NULL
ZRC	NULL
-0	NULL
$	NULL
42	NULL
R	NULL
Cag	NULL
)	NULL
/	NULL
/	NULL
/	NULL
.	NULL

c	NULL
1	NULL
as	NULL
42	NULL
``	NULL
*	NULL
B	NULL
R	NULL
tug	NULL
)	NULL
/	NULL
/	NULL
/	NULL
e8rag	NULL
)	NULL
/	NULL
as	NULL
a2	NULL
``	NULL
*	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

EBl	NULL
and	NULL
R	NULL
effects	NULL
can	NULL
be	NULL
additive	NULL
.	NULL

Quantitative	NULL
S1	NULL
nuclease	NULL
analysis	NULL
of	NULL
B-globin	NULL
RNAs	NULL
expressed	NULL
from	NULL
plasmids	NULL
pG2.899/741	NULL
,	NULL
pG3.741/861	NULL
,	NULL
and	NULL
pG4.741/899	NULL
(	NULL
left	NULL
parts	NULL
of	NULL
panels	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
)	NULL
,	NULL
and	NULL
of	NULL
SV40	NULL
RNAs	NULL
expressed	NULL
from	NULL
plasmid	NULL
pSV2	NULL
$	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
(	NULL
right	NULL
parts	NULL
of	NULL
panels	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
;	NULL
labeled	NULL
``	NULL
pSV2	NULL
$	NULL
internal	NULL
control	NULL
specific	NULL
transcription	NULL
``	NULL
or	NULL
``	NULL
pSV2B	NULL
``	NULL
)	NULL
.	NULL

Plasmid	NULL
pG2.899/741	NULL
(	NULL
A	NULL
)	NULL
,	NULL
plasmid	NULL
pG3.741/861	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
plasmid	NULL
pG4.741/899	NULL
(	NULL
C	NULL
)	NULL
were	NULL
transfected	NULL
in	NULL
HeLa	NULL
cells	NULL
either	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
EB1l-expressing	NULL
vector	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
,	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
R-expressing	NULL
vector	NULL
(	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
)	NULL
,	NULL
or	NULL
with	NULL
a	NULL
constant	NULL
amount	NULL
of	NULL
EBl-expressing	NULL
vector	NULL
plus	NULL
increasing	NULL
amounts	NULL
of	NULL
R-expressing	NULL
vectors	NULL
(	NULL
lanes	NULL
9	NULL
to	NULL
12	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
upper	NULL
parts	NULL
of	NULL
the	NULL
panels	NULL
.	NULL

In	NULL
each	NULL
panel	NULL
,	NULL
an	NULL
insert	NULL
represents	NULL
a	NULL
shorter	NULL
exposure	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
DNA	NULL
constructs	NULL
and	NULL
the	NULL
EB1-	NULL
and	NULL
R-expressing	NULL
vectors	NULL
(	NULL
D	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
the	NULL
upper	NULL
part	NULL
of	NULL
the	NULL
panel	NULL
.	NULL

pSV2B	NULL
was	NULL
cotransfected	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Horizontal	NULL
arrows	NULL
indicate	NULL
specific	NULL
initiation	NULL
sites	NULL
in	NULL
all	NULL
panels	NULL
.	NULL

ZRE-B	NULL
was	NULL
also	NULL
localized	NULL
at	NULL
position	NULL
-113	NULL
upstream	NULL
from	NULL
the	NULL
B-globin	NULL
promoter	NULL
from	NULL
which	NULL
all	NULL
the	NULL
upstream	NULL
elements	NULL
except	NULL
the	NULL
TATA	NULL
box	NULL
had	NULL
been	NULL
deleted	NULL
(	NULL
plasmid	NULL
pG4.741/	NULL
899	NULL
;	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

The	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
in	NULL
this	NULL
plasmid	NULL
was	NULL
no	NULL
longer	NULL
detectable	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
is	NULL
not	NULL
apparent	NULL
on	NULL
the	NULL
autoradiograph	NULL
,	NULL
except	NULL
in	NULL
lane	NULL
4	NULL
,	NULL
the	NULL
basal	NULL
activity	NULL
was	NULL
increased	NULL
by	NULL
increasing	NULL
the	NULL
amount	NULL
of	NULL
EB1	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

The	NULL
B-globin	NULL
promoter	NULL
in	NULL
plasmid	NULL
pG4.741/899	NULL
was	NULL
strongly	NULL
activated	NULL
by	NULL
increasing	NULL
the	NULL
amount	NULL
of	NULL
R-expressing	NULL
vector	NULL
from	NULL
20	NULL
to	NULL
500	NULL
ng	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
and	NULL
then	NULL
reached	NULL
a	NULL
plateau	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
more	NULL
than	NULL
an	NULL
additive	NULL
effect	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
was	NULL
seen	NULL
at	NULL
a	NULL
low	NULL
R	NULL
concentration	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

At	NULL
higher	NULL
R	NULL
concentrations	NULL
,	NULL
an	NULL
additive	NULL
effect	NULL
of	NULL
EB1l	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
,	NULL
lanes	NULL
10	NULL
to	NULL
12	NULL
)	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

The	NULL
three	NULL
plasmids	NULL
were	NULL
also	NULL
compared	NULL
in	NULL
the	NULL
same	NULL
transfection	NULL
.	NULL

The	NULL
distance	NULL
from	NULL
the	NULL
B-globin	NULL
gene	NULL
+1	NULL
at	NULL
which	NULL
the	NULL
RRE	NULL
was	NULL
located	NULL
had	NULL
a	NULL
weak	NULL
effect	NULL
on	NULL
the	NULL
R	NULL
inducibility	NULL
of	NULL
the	NULL
B-globin	NULL
promoter	NULL
and	NULL
was	NULL
not	NULL
dependent	NULL
on	NULL
the	NULL
amount	NULL
of	NULL
R	NULL
expressed	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
B-globin	NULL
upstream	NULL
elements	NULL
reduced	NULL
the	NULL
R	NULL
induction	NULL
by	NULL
a	NULL
factor	NULL
of	NULL
three	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
there	NULL
was	NULL
no	NULL
additive	NULL
effect	NULL
or	NULL
synergy	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
when	NULL
the	NULL
EBl-responsive	NULL
element	NULL
was	NULL
localized	NULL
at	NULL
position	NULL
-549	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
7	NULL
)	NULL
.	NULL

An	NULL
additive	NULL
effect	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
was	NULL
observed	NULL
when	NULL
ZRE-B	NULL
was	NULL
located	NULL
at	NULL
position	NULL
-106	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
.	NULL

A	NULL
more	NULL
than	NULL
additive	NULL
effect	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
was	NULL
observed	NULL
when	NULL
the	NULL
B-globin	NULL
upstream	NULL
elements	NULL
were	NULL
deleted	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
;	NULL
compare	NULL
lanes	NULL
5	NULL
and	NULL
9	NULL
)	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
R-responsive	NULL
element	NULL
was	NULL
not	NULL
dependent	NULL
on	NULL
EB1	NULL
to	NULL
function	NULL
,	NULL
but	NULL
an	NULL
additive	NULL
effect	NULL
between	NULL
R	NULL
and	NULL
EB1	NULL
could	NULL
be	NULL
detected	NULL
when	NULL
the	NULL
EB1-responsive	NULL
ZRE-B	NULL
element	NULL
was	NULL
positioned	NULL
as	NULL
an	NULL
upstream	NULL
element	NULL
and	NULL
at	NULL
low	NULL
R	NULL
concentrations	NULL
.	NULL

In	NULL
no	NULL
case	NULL
could	NULL
we	NULL
detect	NULL
a	NULL
more	NULL
than	NULL
multiplicative	NULL
effect	NULL
corresponding	NULL
to	NULL
synergy	NULL
between	NULL
EB1l	NULL
and	NULL
R.	NULL
DISCUSSION	NULL
We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
DR/DL	NULL
promoter	NULL
contains	NULL
a	NULL
cis-acting	NULL
element	NULL
that	NULL
acts	NULL
as	NULL
an	NULL
enhancer	NULL
inducible	NULL
by	NULL
the	NULL
EBV-encoded	NULL
factor	NULL
R	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
the	NULL
studies	NULL
presented	NULL
here	NULL
,	NULL
careful	NULL
analysis	NULL
of	NULL
the	NULL
R-inducible	NULL
DR	NULL
enhancer	NULL
allowed	NULL
us	NULL
to	NULL
conclude	NULL
that	NULL
an	NULL
R-responsive	NULL
enhancer	NULL
carrying	NULL
54	NULL
%	NULL
of	NULL
the	NULL
R-inducible	NULL
activity	NULL
seems	NULL
to	NULL
be	NULL
included	NULL
in	NULL
a	NULL
47-bp-long	NULL
DNA	NULL
fragment	NULL
containing	NULL
two	NULL
domains	NULL
acting	NULL
cooperatively	NULL
.	NULL

One	NULL
region	NULL
located	NULL
between	NULL
positions	NULL
-741	NULL
and	NULL
-765	NULL
responds	NULL
to	NULL
R	NULL
,	NULL
but	NULL
the	NULL
level	NULL
of	NULL
the	NULL
response	NULL
is	NULL
only	NULL
15	NULL
%	NULL
of	NULL
the	NULL
full	NULL
activity	NULL
.	NULL

None	NULL
of	NULL
the	NULL
subfragments	NULL
in	NULL
this	NULL
region	NULL
possesses	NULL
a	NULL
significant	NULL
R-responsive	NULL
activity	NULL
.	NULL

Even	NULL
the	NULL
double	NULL
palindromic	NULL
region	NULL
TTGTCCCGTGGACAATGTCC	NULL
,	NULL
either	NULL
singly	NULL
or	NULL
duplicated	NULL
,	NULL
did	NULL
not	NULL
respond	NULL
significantly	NULL
to	NULL
R.	NULL
Another	NULL
R-responsive	NULL
enhancer	NULL
has	NULL
been	NULL
characterized	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
PM	NULL
)	NULL
localized	NULL
upstream	NULL
from	NULL
the	NULL
BMLFI	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
3	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
sequence	NULL
AGAATGTCTGC	NULL
severely	NULL
impaired	NULL
R	NULL
induction	NULL
(	NULL
3	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
is	NULL
an	NULL
imperfect	NULL
duplication	NULL
of	NULL
a	NULL
sequence	NULL
conserved	NULL
between	NULL
the	NULL
two	NULL
enhancers	NULL
CCGTGGAG	NULL
or	NULL
CAAT	NULL
GTC	NULL
(	NULL
25	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
38-bp	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
region	NULL
conserved	NULL
in	NULL
promoter	NULL
PM	NULL
did	NULL
not	NULL
confer	NULL
R	NULL
responsiveness	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
bidirectional	NULL
mutagenesis	NULL
in	NULL
the	NULL
PM	NULL
promoter	NULL
RRE	NULL
clearly	NULL
shows	NULL
that	NULL
this	NULL
enhancer	NULL
is	NULL
also	NULL
composed	NULL
of	NULL
several	NULL
elements	NULL
acting	NULL
cooperatively	NULL
(	NULL
M.	NULL
Buisson	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

The	NULL
region	NULL
consisting	NULL
of	NULL
positions	NULL
-761	NULL
to	NULL
-783	NULL
is	NULL
not	NULL
responsive	NULL
to	NULL
R	NULL
but	NULL
strongly	NULL
increased	NULL
the	NULL
R	NULL
responsiveness	NULL
when	NULL
associated	NULL
with	NULL
the	NULL
region	NULL
comprising	NULL
positions	NULL
-741	NULL
to	NULL
-765	NULL
.	NULL

This	NULL
region	NULL
might	NULL
bind	NULL
a	NULL
cellular	NULL
factor	NULL
acting	NULL
cooperatively	NULL
when	NULL
linked	NULL
to	NULL
an	NULL
activated	NULL
RRE	NULL
.	NULL

Indeed	NULL
,	NULL
deletion	NULL
of	NULL
this	NULL
region	NULL
impairs	NULL
the	NULL
constitutive	NULL
activity	NULL
of	NULL
the	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
7	NULL
)	NULL
.	NULL

One	NULL
region	NULL
of	NULL
the	NULL
enhancer	NULL
,	NULL
positions	NULL
-752	NULL
to	NULL
-781	NULL
,	NULL
contains	NULL
one	NULL
copy	NULL
of	NULL
the	NULL
palindromic	NULL
sequence	NULL
GTGGACAATGTCC	NULL
linked	NULL
to	NULL
the	NULL
region	NULL
comprising	NULL
positions	NULL
-761	NULL
to	NULL
-783	NULL
.	NULL

However	NULL
,	NULL
this	NULL
region	NULL
has	NULL
only	NULL
7	NULL
%	NULL
of	NULL
the	NULL
R-induced	NULL
activity	NULL
of	NULL
mutant	NULL
pG2.752/	NULL
899	NULL
,	NULL
which	NULL
contains	NULL
both	NULL
regions	NULL
and	NULL
upstream	NULL
sequences	NULL
.	NULL

There	NULL
must	NULL
be	NULL
another	NULL
RRE	NULL
which	NULL
compensates	NULL
for	NULL
the	NULL
partial	NULL
loss	NULL
of	NULL
positions	NULL
-737	NULL
to	NULL
-752	NULL
in	NULL
mutant	NULL
pG2.899/	NULL
752	NULL
.	NULL

There	NULL
is	NULL
indeed	NULL
a	NULL
third	NULL
region	NULL
responding	NULL
to	NULL
R	NULL
,	NULL
localized	NULL
VoL	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
between	NULL
positions	NULL
-812	NULL
and	NULL
-899	NULL
,	NULL
and	NULL
the	NULL
elements	NULL
that	NULL
mediate	NULL
R	NULL
activation	NULL
in	NULL
this	NULL
region	NULL
have	NULL
yet	NULL
to	NULL
be	NULL
character-ized	NULL
.	NULL

Whether	NULL
the	NULL
RRE	NULL
motif	NULL
and	NULL
the	NULL
more	NULL
remote	NULL
putative	NULL
RRE	NULL
bind	NULL
cellular	NULL
factors	NULL
or	NULL
bind	NULL
R	NULL
or	NULL
both	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
.	NULL

Since	NULL
the	NULL
enhancer	NULL
has	NULL
a	NULL
weak	NULL
but	NULL
clear	NULL
constitutive	NULL
activity	NULL
and	NULL
this	NULL
activity	NULL
is	NULL
reduced	NULL
by	NULL
progressive	NULL
deletion	NULL
of	NULL
sequences	NULL
,	NULL
there	NULL
must	NULL
be	NULL
cellular	NULL
factors	NULL
binding	NULL
to	NULL
this	NULL
element	NULL
.	NULL

Comparison	NULL
of	NULL
DNase	NULL
I	NULL
footprints	NULL
by	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
HeLa	NULL
cells	NULL
and	NULL
HeLa	NULL
expressing	NULL
R	NULL
constitutively	NULL
shows	NULL
that	NULL
there	NULL
are	NULL
constitutive	NULL
and	NULL
R-induced	NULL
footprints	NULL
covering	NULL
the	NULL
ORI	NULL
,	NULL
,	NULL
,	NULL
and	NULL
BMLFI	NULL
R-responsive	NULL
enhancers	NULL
(	NULL
H.	NULL
Gruffat	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
described	NULL
above	NULL
seems	NULL
to	NULL
fall	NULL
in	NULL
the	NULL
multidomain	NULL
enhancer	NULL
family	NULL
(	NULL
15	NULL
)	NULL
and	NULL
is	NULL
probably	NULL
composed	NULL
of	NULL
several	NULL
basic	NULL
elements	NULL
,	NULL
or	NULL
enhansons	NULL
,	NULL
which	NULL
are	NULL
weak	NULL
RREs	NULL
(	NULL
34	NULL
)	NULL
.	NULL

These	NULL
enhansons	NULL
have	NULL
to	NULL
be	NULL
identified	NULL
.	NULL

This	NULL
must	NULL
be	NULL
done	NULL
by	NULL
characterization	NULL
of	NULL
protein-binding	NULL
sites	NULL
as	NULL
well	NULL
as	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

Using	NULL
different	NULL
EBV	NULL
promoter-CAT	NULL
constructs	NULL
,	NULL
others	NULL
have	NULL
reported	NULL
that	NULL
the	NULL
DR/DL	NULL
enhancer	NULL
was	NULL
in	NULL
fact	NULL
an	NULL
EB1l-inducible	NULL
enhancer	NULL
with	NULL
B-cell	NULL
specificity	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
these	NULL
authors	NULL
could	NULL
detect	NULL
the	NULL
enhancer	NULL
activity	NULL
in	NULL
EBV	NULL
genome-positive	NULL
IB4	NULL
cells	NULL
only	NULL
when	NULL
EB1	NULL
was	NULL
expressed	NULL
.	NULL

This	NULL
simply	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
R	NULL
is	NULL
induced	NULL
by	NULL
EB1	NULL
in	NULL
EBV	NULL
genome-positive	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
25	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
also	NULL
be	NULL
noted	NULL
that	NULL
EB1l	NULL
and	NULL
R	NULL
induce	NULL
EB2	NULL
(	NULL
the	NULL
BMLFl	NULL
ORF-encoded	NULL
product	NULL
)	NULL
in	NULL
EBV	NULL
genome-positive	NULL
B	NULL
cells	NULL
.	NULL

EB2	NULL
is	NULL
a	NULL
posttranscriptional	NULL
transactivator	NULL
which	NULL
very	NULL
efficiently	NULL
increases	NULL
CAT	NULL
enzyme	NULL
activity	NULL
without	NULL
notably	NULL
affecting	NULL
the	NULL
amount	NULL
of	NULL
CAT	NULL
RNA	NULL
expressed	NULL
from	NULL
different	NULL
promoter-CAT	NULL
chimeric	NULL
genes	NULL
(	NULL
3	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
experiments	NULL
in	NULL
which	NULL
CAT	NULL
enzyme	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
EBl	NULL
in	NULL
EBV	NULL
genome-positive	NULL
cells	NULL
have	NULL
very	NULL
little	NULL
meaning	NULL
and	NULL
reflect	NULL
additive	NULL
(	NULL
maybe	NULL
synergic	NULL
)	NULL
transcriptional	NULL
and	NULL
posttranscriptional	NULL
effects	NULL
specific	NULL
for	NULL
CAT	NULL
transcripts	NULL
.	NULL

We	NULL
have	NULL
reported	NULL
that	NULL
the	NULL
DR	NULL
promoter	NULL
RRE	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
EB1	NULL
in	NULL
EBV	NULL
genome-negative	NULL
B	NULL
cells	NULL
but	NULL
was	NULL
instead	NULL
induced	NULL
by	NULL
R	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

We	NULL
also	NULL
show	NULL
in	NULL
this	NULL
paper	NULL
that	NULL
the	NULL
R-inducible	NULL
enhancer	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
EB1	NULL
in	NULL
HeLa	NULL
cells	NULL
when	NULL
positioned	NULL
like	NULL
an	NULL
enhancer	NULL
in	NULL
a	NULL
very	NULL
general	NULL
sense	NULL
.	NULL

Moreover	NULL
,	NULL
at	NULL
high	NULL
R	NULL
concentrations	NULL
,	NULL
the	NULL
B-globin	NULL
promoter	NULL
(	NULL
this	NULL
report	NULL
)	NULL
and	NULL
the	NULL
BMLF1	NULL
promoter	NULL
(	NULL
M.	NULL
Buisson	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
were	NULL
activated	NULL
to	NULL
saturation	NULL
,	NULL
and	NULL
no	NULL
additive	NULL
effect	NULL
of	NULL
EB1	NULL
could	NULL
be	NULL
detected	NULL
.	NULL

There	NULL
is	NULL
,	NULL
however	NULL
,	NULL
an	NULL
EBl-binding	NULL
site	NULL
(	NULL
ZRE-B	NULL
)	NULL
located	NULL
-843	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
DR	NULL
promoter	NULL
initiation	NULL
site	NULL
in	NULL
the	NULL
region	NULL
defined	NULL
originally	NULL
as	NULL
the	NULL
DR	NULL
enhancer	NULL
B	NULL
domain	NULL
(	NULL
5	NULL
)	NULL
.	NULL

This	NULL
ZRE-B	NULL
did	NULL
not	NULL
confer	NULL
a	NULL
significant	NULL
(	NULL
more	NULL
than	NULL
twofold	NULL
)	NULL
EB1	NULL
responsiveness	NULL
to	NULL
the	NULL
B-globin	NULL
promoter	NULL
,	NULL
either	NULL
alone	NULL
or	NULL
linked	NULL
to	NULL
the	NULL
RRE	NULL
,	NULL
when	NULL
localized	NULL
over	NULL
500	NULL
bp	NULL
from	NULL
the	NULL
B-globin	NULL
cap	NULL
site	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
not	NULL
part	NULL
of	NULL
the	NULL
enhancer	NULL
.	NULL

However	NULL
,	NULL
EBl	NULL
and	NULL
R	NULL
effects	NULL
can	NULL
be	NULL
additive	NULL
,	NULL
when	NULL
the	NULL
amount	NULL
of	NULL
R	NULL
is	NULL
greatly	NULL
reduced	NULL
and	NULL
when	NULL
ZRE-B	NULL
is	NULL
positioned	NULL
close	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

This	NULL
also	NULL
turned	NULL
out	NULL
to	NULL
be	NULL
the	NULL
case	NULL
for	NULL
the	NULL
promoter	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
BMLFl-encoded	NULL
posttranscriptional	NULL
activator	NULL
EB2	NULL
.	NULL

The	NULL
RRE	NULL
is	NULL
located	NULL
at	NULL
position	NULL
-300	NULL
,	NULL
and	NULL
the	NULL
EB1/APl/jun-fos-responsive	NULL
element	NULL
is	NULL
located	NULL
at	NULL
position	NULL
-100	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
synergy	NULL
between	NULL
EB1	NULL
and	NULL
R	NULL
on	NULL
this	NULL
promoter	NULL
,	NULL
since	NULL
the	NULL
effect	NULL
observed	NULL
is	NULL
more	NULL
than	NULL
multiplicative	NULL
,	NULL
but	NULL
only	NULL
when	NULL
the	NULL
amount	NULL
of	NULL
R	NULL
is	NULL
greatly	NULL
reduced	NULL
(	NULL
M.	NULL
Buisson	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

The	NULL
RRE	NULL
is	NULL
also	NULL
clearly	NULL
active	NULL
on	NULL
the	NULL
EA-R	NULL
promoter	NULL
(	NULL
11	NULL
)	NULL
in	NULL
transient	NULL
expression	NULL
assays	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
to	NULL
be	NULL
established	NULL
whether	NULL
this	NULL
enhancer	NULL
influences	NULL
transcription	NULL
initiation	NULL
from	NULL
the	NULL
DR	NULL
promoter	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
in	NULL
ORL	NULL
,	NULL
,	NULL
ENHANCER	NULL
TRANSACTIVATION	NULL
2817	NULL
HeLa	NULL
cells	NULL
,	NULL
R	NULL
by	NULL
itself	NULL
activates	NULL
the	NULL
DR	NULL
promoter	NULL
either	NULL
linked	NULL
to	NULL
the	NULL
IR4	NULL
gene	NULL
or	NULL
to	NULL
the	NULL
B-globin	NULL
gene	NULL
,	NULL
but	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
is	NULL
much	NULL
lower	NULL
than	NULL
that	NULL
observed	NULL
with	NULL
EB1	NULL
,	NULL
and	NULL
there	NULL
is	NULL
no	NULL
synergy	NULL
between	NULL
EB1	NULL
and	NULL
R.	NULL
This	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
EB1	NULL
is	NULL
the	NULL
upstream	NULL
factor	NULL
for	NULL
the	NULL
DR	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
EB1	NULL
,	NULL
the	NULL
DR	NULL
promoter	NULL
is	NULL
almost	NULL
restricted	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
element	NULL
,	NULL
and	NULL
R	NULL
can	NULL
not	NULL
efficiently	NULL
activate	NULL
transcription	NULL
when	NULL
its	NULL
responsive	NULL
elements	NULL
are	NULL
localized	NULL
far	NULL
upstream	NULL
from	NULL
a	NULL
TATA	NULL
box	NULL
alone	NULL
(	NULL
N.	NULL
Moreno	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
when	NULL
the	NULL
enhancer	NULL
is	NULL
localized	NULL
close	NULL
to	NULL
the	NULL
DR	NULL
TATA	NULL
box	NULL
,	NULL
it	NULL
is	NULL
strongly	NULL
activated	NULL
by	NULL
R	NULL
,	NULL
and	NULL
there	NULL
is	NULL
synergy	NULL
between	NULL
EB1	NULL
and	NULL
R.	NULL
Since	NULL
EB1	NULL
is	NULL
not	NULL
an	NULL
enhancer	NULL
factor	NULL
,	NULL
why	NULL
is	NULL
there	NULL
an	NULL
EB1-binding	NULL
site	NULL
located	NULL
in	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
,	NULL
-843	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
DR	NULL
promoter	NULL
major	NULL
initiation	NULL
site	NULL
?	NULL

This	NULL
EB1l-binding	NULL
site	NULL
is	NULL
part	NULL
of	NULL
the	NULL
EA-R	NULL
promoter	NULL
,	NULL
which	NULL
is	NULL
an	NULL
early	NULL
promoter	NULL
inducible	NULL
by	NULL
EB1	NULL
and	NULL
by	NULL
R	NULL
,	NULL
whose	NULL
putative	NULL
TATA	NULL
box	NULL
is	NULL
located	NULL
-970	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
DL	NULL
promoter	NULL
cap	NULL
site	NULL
and	NULL
in	NULL
the	NULL
rightward	NULL
direction	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
DL	NULL
promoter	NULL
and	NULL
the	NULL
DR	NULL
promoter	NULL
are	NULL
homologous	NULL
(	NULL
26	NULL
)	NULL
and	NULL
share	NULL
the	NULL
R-responsive	NULL
enhancer	NULL
,	NULL
ZRE-B	NULL
is	NULL
probably	NULL
conserved	NULL
during	NULL
the	NULL
duplication	NULL
of	NULL
the	NULL
two	NULL
promoters	NULL
.	NULL

One	NULL
other	NULL
explanation	NULL
is	NULL
that	NULL
ZRE-B	NULL
has	NULL
a	NULL
function	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
origin	NULL
of	NULL
replication	NULL
overlapping	NULL
with	NULL
the	NULL
DR	NULL
promoter	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Conrad	NULL
B.	NULL
Bluink	NULL
for	NULL
editorial	NULL
assistance	NULL
and	NULL
P.	NULL
Jalinot	NULL
for	NULL
plasmids	NULL
pG1	NULL
and	NULL
pG2	NULL
.	NULL

N.M.	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
Carabobo	NULL
University	NULL
,	NULL
Valencia	NULL
,	NULL
Venezuela	NULL
.	NULL

This	NULL
work	NULL
was	NULL
financially	NULL
supported	NULL
by	NULL
the	NULL
Fédération	NULL
Nationale	NULL
des	NULL
Centres	NULL
de	NULL
Lutte	NULL
contre	NULL
le	NULL
Cancer	NULL
,	NULL
by	NULL
the	NULL
Institut	NULL
National	NULL
de	NULL
la	NULL
Santé	NULL
et	NULL
de	NULL
la	NULL
Recherche	NULL
Médicale	NULL
(	NULL
contract	NULL
871015	NULL
)	NULL
,	NULL
and	NULL
by	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
(	NULL
grant	NULL
6810	NULL
)	NULL
.	NULL

H.G	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
an	NULL
MRT	NULL
fellowship	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Baer	NULL
,	NULL
R.	NULL
,	NULL
A.	NULL
T.	NULL
Bankier	NULL
,	NULL
M.	NULL
D.	NULL
Biggin	NULL
,	NULL
P.	NULL
L.	NULL
Deininger	NULL
,	NULL
P.	NULL
L.	NULL
Farrel	NULL
,	NULL
T.	NULL
G.	NULL
Gibson	NULL
,	NULL
G.	NULL
Hatfull	NULL
,	NULL
G.	NULL
S.	NULL
Hudson	NULL
,	NULL
S.	NULL
C.	NULL
Satchwell	NULL
,	NULL
C.	NULL
Seguin	NULL
,	NULL
P.	NULL
S.	NULL
Tufnell	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Barrell	NULL
.	NULL

1984	NULL
.	NULL

DNA	NULL
sequence	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
B95-8	NULL
Epstein-Barr	NULL
virus	NULL
genome	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
310:207-211	NULL
.	NULL

2	NULL
.	NULL

Bodescot	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
Perricaudet	NULL
.	NULL

1986	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
mRNAs	NULL
produced	NULL
by	NULL
alternative	NULL
splicing	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14:7103-7114	NULL
.	NULL

3	NULL
.	NULL

Buisson	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
M.-C.	NULL
Trescol-Biemont	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
B.	NULL
Durand	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early	NULL
protein	NULL
EB2	NULL
is	NULL
a	NULL
posttranscriptional	NULL
activator	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
EBV	NULL
transcription	NULL
factors	NULL
EB1	NULL
and	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:5276-5284	NULL
.	NULL

4	NULL
.	NULL

Chavrier	NULL
,	NULL
P.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
A.	NULL
Chevallier-Greco	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
early	NULL
promoter	NULL
DR	NULL
contains	NULL
a	NULL
cis-acting	NULL
element	NULL
responsive	NULL
to	NULL
the	NULL
EBV	NULL
transactivator	NULL
EB1	NULL
and	NULL
an	NULL
enhancer	NULL
with	NULL
constitutive	NULL
and	NULL
inducible	NULL
activities	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:607-614	NULL
.	NULL

5	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
DR	NULL
enhancer	NULL
contains	NULL
two	NULL
functionally	NULL
different	NULL
domains	NULL
:	NULL
domain	NULL
A	NULL
is	NULL
constitutive	NULL
and	NULL
cell	NULL
specific	NULL
,	NULL
domain	NULL
B	NULL
is	NULL
transactivated	NULL
by	NULL
the	NULL
EBV	NULL
early	NULL
protein	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:615-623	NULL
.	NULL

6	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
encoded	NULL
trans-acting	NULL
factors	NULL
,	NULL
EB1	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
early	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

7	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
G.	NULL
Urier	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
EBV	NULL
early	NULL
promoter	NULL
is	NULL
activated	NULL
by	NULL
two	NULL
viral	NULL
encoded	NULL
trans-acting	NULL
factors	NULL
,	NULL
2818	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

GRUFFAT	NULL
ET	NULL
AL	NULL
.	NULL

EB1	NULL
and	NULL
EB2	NULL
,	NULL
p.	NULL
157-161	NULL
.	NULL

In	NULL
D.	NULL
L.	NULL
Ablashi	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
human	NULL
diseases	NULL
.	NULL

Humana	NULL
Press	NULL
,	NULL
Clifton	NULL
,	NULL
N.J.	NULL
.	NULL

Cho	NULL
,	NULL
M.-S.	NULL
,	NULL
K.-T.	NULL
Jeang	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1985	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigen	NULL
and	NULL
inducible	NULL
expression	NULL
of	NULL
this	NULL
60-kilodalton	NULL
nuclear	NULL
protein	NULL
in	NULL
transfected	NULL
fibroblast	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

56:852-859.	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1985	NULL
.	NULL

Activation	NULL
of	NULL
expression	NULL
of	NULL
latent	NULL
Epstein-Barr	NULL
herpesvirus	NULL
after	NULL
transfer	NULL
with	NULL
a	NULL
small	NULL
cloned	NULL
subfragment	NULL
of	NULL
heterogeneous	NULL
viral	NULL
DNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:4085-4089	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
E.	NULL
Grogan	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
2.7-Kb	NULL
rearranged	NULL
DNA	NULL
fragment	NULL
from	NULL
Epstein-Barr	NULL
virus	NULL
capable	NULL
of	NULL
disruption	NULL
of	NULL
latency	NULL
.	NULL

Cancer	NULL
Cells	NULL
4:517-523	NULL
.	NULL

Cox	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
:	NULL
313-321	NULL
.	NULL

Dambaugh	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1982	NULL
.	NULL

Identification	NULL
and	NULL
nucle-otide	NULL
sequences	NULL
of	NULL
two	NULL
similar	NULL
tandem	NULL
direct	NULL
repeats	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

44:823-833	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
C.	NULL
M.	NULL
Rooney	NULL
,	NULL
and	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
BZLFl	NULL
transactivator	NULL
specifically	NULL
binds	NULL
to	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
and	NULL
is	NULL
related	NULL
to	NULL
c-fos	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:127-132	NULL
.	NULL

Freese	NULL
,	NULL
U.	NULL
K.	NULL
,	NULL
G.	NULL
Laux	NULL
,	NULL
J.	NULL
Hudewentz	NULL
,	NULL
E.	NULL
Schwarz	NULL
,	NULL
and	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
.	NULL

1983	NULL
.	NULL

Two	NULL
distinct	NULL
clusters	NULL
of	NULL
partially	NULL
homologous	NULL
small	NULL
repeats	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
are	NULL
transcribed	NULL
upon	NULL
induction	NULL
of	NULL
an	NULL
abortive	NULL
or	NULL
lytic	NULL
cycle	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

48	NULL
:	NULL
731-743	NULL
.	NULL

Fromental	NULL
,	NULL
C.	NULL
,	NULL
M.	NULL
Kanno	NULL
,	NULL
H.	NULL
Nomiyama	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1988	NULL
.	NULL

Cooperativity	NULL
and	NULL
hierarchical	NULL
levels	NULL
of	NULL
functional	NULL
organization	NULL
in	NULL
the	NULL
SV40	NULL
enhancer	NULL
.	NULL

Cell	NULL
54:943-953	NULL
.	NULL

Graham	NULL
,	NULL
F.	NULL
L.	NULL
,	NULL
and	NULL
A.	NULL
J	NULL
.	NULL

Van	NULL
Der	NULL
Eb	NULL
.	NULL

1973	NULL
.	NULL

A	NULL
new	NULL
technique	NULL
for	NULL
the	NULL
assay	NULL
of	NULL
infectivity	NULL
of	NULL
human	NULL
adenovirus	NULL
5	NULL
DNA	NULL
.	NULL

Virology	NULL
52:456-467	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
ORJ	NULL
,	NULL
,	NULL
,	NULL
,	NULL
a	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Cell	NULL
55:427-433	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
M.	NULL
Lieberman	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
,	NULL
R	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
cytoplasmic	NULL
early	NULL
antigen	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2274-2284	NULL
.	NULL

Hayward	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
S.	NULL
G.	NULL
Lazarowitz	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Hayward	NULL
.	NULL

1982	NULL
.	NULL

Organization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
molecule	NULL
.	NULL

II	NULL
.	NULL

Fine	NULL
mapping	NULL
of	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
internal	NULL
repeat	NULL
cluster	NULL
of	NULL
B95-8	NULL
and	NULL
identification	NULL
of	NULL
additional	NULL
small	NULL
tandem	NULL
repeats	NULL
adjacent	NULL
to	NULL
the	NULL
HR-1	NULL
deletion	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

43:201-212	NULL
.	NULL

Hennessy	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Fennewald	NULL
,	NULL
M.	NULL
Hummel	NULL
,	NULL
T.	NULL
Cole	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1984	NULL
.	NULL

A	NULL
membrane	NULL
protein	NULL
encoded	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
latent	NULL
growth	NULL
transforming	NULL
infection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:7207-7211	NULL
.	NULL

Hudwentz	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Delius	NULL
,	NULL
U.	NULL
K.	NULL
Freese	NULL
,	NULL
U.	NULL
Zimber	NULL
,	NULL
and	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
.	NULL

1982	NULL
.	NULL

Two	NULL
distinct	NULL
regions	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
genome	NULL
with	NULL
sequence	NULL
homologies	NULL
have	NULL
the	NULL
same	NULL
orientation	NULL
and	NULL
involve	NULL
small	NULL
tandem	NULL
repeats	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

1:21-26	NULL
.	NULL

Jalinot	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
C.	NULL
Kedinger	NULL
.	NULL

1986	NULL
.	NULL

Negative	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
Ela-inducible	NULL
enhancer	NULL
of	NULL
the	NULL
adenovirus-2	NULL
early	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

J.	NULL
Ella	NULL
promoter	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14:2651-2669	NULL
.	NULL

Jeang	NULL
,	NULL
K.-T.	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1983	NULL
.	NULL

Organization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
molecule	NULL
.	NULL

III	NULL
.	NULL

Location	NULL
of	NULL
the	NULL
P3HR-1	NULL
deletion	NULL
junction	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
NofI	NULL
repeat	NULL
units	NULL
that	NULL
form	NULL
part	NULL
of	NULL
the	NULL
template	NULL
for	NULL
an	NULL
abundant	NULL
12-O-tetrade-canoylphorbol-13-acetate-induced	NULL
mRNA	NULL
transcript	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

48:135-148	NULL
.	NULL

Jones	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Griffin	NULL
.	NULL

1983	NULL
.	NULL

Clustered	NULL
repeat	NULL
sequences	NULL
in	NULL
the	NULL
genome	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:3919-3937	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
M.	NULL
Smith	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BMLF1	NULL
promoter	NULL
contains	NULL
an	NULL
enhancer	NULL
element	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
the	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3878-3883	NULL
.	NULL

Laux	NULL
,	NULL
G.	NULL
,	NULL
U.	NULL
K.	NULL
Freese	NULL
,	NULL
and	NULL
G.	NULL
Bornkamm	NULL
.	NULL

1985	NULL
.	NULL

Structure	NULL
and	NULL
evolution	NULL
of	NULL
two	NULL
related	NULL
transcription	NULL
units	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
carrying	NULL
small	NULL
tandem	NULL
repeats	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

56:987-995	NULL
.	NULL

Laux	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Perricaudet	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
spliced	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
expressed	NULL
in	NULL
immortalized	NULL
lymphocytes	NULL
is	NULL
created	NULL
by	NULL
circularization	NULL
of	NULL
the	NULL
linear	NULL
viral	NULL
genome	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:769-744	NULL
.	NULL

Lerner	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
Andrews	NULL
,	NULL
G.	NULL
Miller	NULL
,	NULL
and	NULL
J.	NULL
Steitz	NULL
.	NULL

1981	NULL
.	NULL

Two	NULL
small	NULL
RNAs	NULL
encoded	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
complexed	NULL
with	NULL
proteins	NULL
are	NULL
precipitated	NULL
by	NULL
antibodies	NULL
from	NULL
patients	NULL
with	NULL
systemic	NULL
lupus	NULL
erythematosus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78	NULL
:	NULL
805-809	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Hardwick	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1989	NULL
.	NULL

Responsiveness	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
NotI	NULL
repeat	NULL
promoter	NULL
to	NULL
the	NULL
Z	NULL
transactivator	NULL
is	NULL
mediated	NULL
in	NULL
a	NULL
cell-type-specific	NULL
manner	NULL
by	NULL
two	NULL
independent	NULL
signal	NULL
regions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3040-3050	NULL
.	NULL

Manet	NULL
,	NULL
E.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
M.	NULL
C.	NULL
Trescol-Biemont	NULL
,	NULL
N.	NULL
Moreno	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
J.	NULL
F.	NULL
Giot	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
bicistronic	NULL
mRNAs	NULL
generated	NULL
by	NULL
facultative	NULL
splicing	NULL
code	NULL
for	NULL
two	NULL
transcriptional	NULL
trans-activators	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1819-1826	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
1985	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
,	NULL
p.	NULL
563-590	NULL
.	NULL

In	NULL
B	NULL
.	NULL

Fields	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
Publishers	NULL
,	NULL
New	NULL
York	NULL
.	NULL

__	NULL
Miller	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Rabson	NULL
,	NULL
and	NULL
L.	NULL
Heston	NULL
.	NULL

1984	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
with	NULL
heterogeneous	NULL
DNA	NULL
disrupts	NULL
latency	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

50:174-182	NULL
.	NULL

Nilson	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Abrahmsén	NULL
,	NULL
and	NULL
M.	NULL
Uhién	NULL
.	NULL

1985	NULL
.	NULL

Immobilisation	NULL
and	NULL
purification	NULL
of	NULL
enzymes	NULL
with	NULL
staphylococcal	NULL
protein	NULL
A	NULL
gene	NULL
fusion	NULL
vectors	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

4:1075-1080	NULL
.	NULL

Ondek	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Gloss	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
SV40	NULL
enhancer	NULL
contains	NULL
two	NULL
distinct	NULL
levels	NULL
of	NULL
organization	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:40-45	NULL
.	NULL

Sample	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1989	NULL
.	NULL

Two	NULL
related	NULL
Epstein-Barr	NULL
virus	NULL
membrane	NULL
proteins	NULL
are	NULL
encoded	NULL
by	NULL
separate	NULL
genes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:933-937	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Shimizu	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1986.	NULL
trans	NULL
Activation	NULL
of	NULL
the	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:1016-1022	NULL
.	NULL

Urier	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
protein	NULL
EBl	NULL
activates	NULL
transcription	NULL
from	NULL
different	NULL
responsive	NULL
elements	NULL
including	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1447-1453	NULL
.	NULL

Zur	NULL
Hausen	NULL
,	NULL
H.	NULL
,	NULL
E.	NULL
J.	NULL
O'Neil	NULL
,	NULL
U.	NULL
K.	NULL
Freese	NULL
,	NULL
and	NULL
E.	NULL
Hecher	NULL
.	NULL

1978	NULL
.	NULL

Persisting	NULL
oncogenic	NULL
herpes-virus	NULL
induced	NULL
by	NULL
tumor	NULL
promoter	NULL
TPA	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
272:373-375	NULL
.	NULL

